prednisone has been researched along with Benign Neoplasms in 320 studies
Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.
prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Repeated oral doses of metoclopramide (50 mg) and prednisone (25 mg) completely prevented nausea and vomiting (N + V) in approximately 50% and substantially reduced N + V in an additional 27%-36% of 56 chemotherapy courses in 30 consecutive cancer patients who were receiving primarily cisplatin." | 7.67 | Effective control of chemotherapy-induced nausea and vomiting with oral prednisone and metoclopramide. ( Bachmann-Mettler, I; Glaus, A; Senn, HJ, 1984) |
| "The results of a five-year study of chlorambucil in patients suffering from rheumatoid arthritis are presented." | 7.65 | Rheumatoid arthritis treated with chlorambucil: a five-year follow-up. ( Thorpe, P, 1976) |
| "Prednisone was given orally at 60 mg/m(2) per day for five consecutive days within each 28-day cycle." | 6.75 | A phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphomas. ( Conley, BA; Dancey, J; Doroshow, JH; Figg, WD; Gardner, ER; Gutierrez, ME; Kummar, S; Melillo, G; Murgo, AJ; Sausville, EA, 2010) |
| "In a randomized trial of 58 cancer patients receiving strongly emetogenic cytostatic drugs (cisplatin or comparable cytostatic agents, alone or in combination), the anti-emetic action of oral metoclopramide was tested, alone or combined with prednisone." | 6.66 | [Prevention of nausea and emesis during cytostatic therapy. Antiemetic efficacy of high-dosage oral metoclopramide without and with prednisone]. ( Bachmann-Mettler, I; Glaus, A; Köhler, M; Senn, HJ; Weigand, W, 1986) |
| "Data were obtained from a Phase II, randomized, double-blind Bayesian pick-the-winner trial of prednisone and pomalidomide in patients with MPN-associated myelofibrosis and anemia (red blood cell-transfusion dependence)." | 5.19 | Use of the Functional Assessment of Cancer Therapy--anemia in persons with myeloproliferative neoplasm-associated myelofibrosis and anemia. ( Cervantes, F; Gale, RP; Hudgens, S; Khan, ZM; Mesa, R; Passamonti, F; Rivera, C; Tefferi, A; Tencer, T; Verstovsek, S, 2014) |
| "We reviewed published studies reporting phase II and III clinical trials of dose-dense regimens for breast cancer and NHL, TAC (docetaxel, adriamycin, cyclophosphamide) chemotherapy for breast cancer, and infusional 5-fluorouracil-based regimens for colorectal cancer." | 4.83 | Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer. ( Avritscher, EB; Bekele, BN; Cooksley, CD; Elting, LS; Jones, JA; Michelet, M, 2006) |
| " In addition, characterization of the UGT1A locus and genetic studies directed at understanding the role of bilirubin glucuronidation and the biochemical basis of the clinical symptoms found in unconjugated hyperbilirubinemia have uncovered the structural gene polymorphisms associated with Crigler-Najjar's and Gilbert's syndrome." | 4.80 | Human UDP-glucuronosyltransferases: metabolism, expression, and disease. ( Strassburg, CP; Tukey, RH, 2000) |
| "We examined the occurrence of neoplasms among 1008 renal transplant recipients treated with a sirolimus-cyclosporine (CsA) +/- prednisone (Pred) regimen." | 3.73 | Individualization of immunosuppressive therapy. III. Sirolimus associated with a reduced incidence of malignancy. ( Buell, JF; Kahan, BD; Woodle, S; Yakupoglu, YK, 2006) |
| "Repeated oral doses of metoclopramide (50 mg) and prednisone (25 mg) completely prevented nausea and vomiting (N + V) in approximately 50% and substantially reduced N + V in an additional 27%-36% of 56 chemotherapy courses in 30 consecutive cancer patients who were receiving primarily cisplatin." | 3.67 | Effective control of chemotherapy-induced nausea and vomiting with oral prednisone and metoclopramide. ( Bachmann-Mettler, I; Glaus, A; Senn, HJ, 1984) |
| "To determine the frequency, predisposing factors and consequences of extrahepatic malignancy following long-term immunosuppressive therapy of severe HBsAg-negative chronic active hepatitis, 149 patients who had received prednisone (20 mg daily) or prednisone (10 mg daily) in combination with azathioprine (50 mg daily) for at least 6 months were evaluated systematically for 109 +/- 5 months (range: 7 to 223 months)." | 3.67 | Extrahepatic malignancy following long-term immunosuppressive therapy of severe hepatitis B surface antigen-negative chronic active hepatitis. ( Beaver, SJ; Czaja, AJ; Go, VL; Wang, KK, 1989) |
| "Subacute polyneuropathy that responded to prednisone was the initial symptom in two patients, one of whom was later found to have histiocytic lymphoma and the other, chronic lymphocytic leukemia." | 3.66 | Lymphoma and leukemia manifested by steroid-responsive polyneuropathy. ( Farrell, DF; Knauss, TA; Sumi, SM, 1983) |
| "The results of a five-year study of chlorambucil in patients suffering from rheumatoid arthritis are presented." | 3.65 | Rheumatoid arthritis treated with chlorambucil: a five-year follow-up. ( Thorpe, P, 1976) |
| "Prednisone was co-administered for 2 weeks in Cycle 1." | 3.01 | Phase 1 study of 2 high dose intensity schedules of the pan-Notch inhibitor crenigacestat (LY3039478) in combination with prednisone in patients with advanced or metastatic cancer. ( Azaro, A; Baldini, C; Benhadji, KA; Lithio, A; Massard, C; Oakley, G; Rodon, J; Soria, JC; Yuen, E, 2021) |
| "Survivors of Hodgkin lymphoma (HL) have an increased risk of subsequent malignant neoplasms (SMNs)." | 3.01 | Subsequent malignant neoplasms among children with Hodgkin lymphoma: a report from the Children's Oncology Group. ( Bush, R; Buxton, A; Constine, LS; Friedman, DL; Giulino-Roth, L; Kelly, KM; Pei, Q; Schwartz, CL; Wolden, SL; Wu, Y, 2021) |
| "Prednisone was given orally at 60 mg/m(2) per day for five consecutive days within each 28-day cycle." | 2.75 | A phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphomas. ( Conley, BA; Dancey, J; Doroshow, JH; Figg, WD; Gardner, ER; Gutierrez, ME; Kummar, S; Melillo, G; Murgo, AJ; Sausville, EA, 2010) |
| "The incidence of cancer was 22." | 2.73 | 20-year follow-up results of a randomized controlled trial comparing antilymphocyte globulin induction to no induction in renal transplant patients. ( Benoit, G; Cantarovich, M; Charpentier, B; Durrbach, A; Hiesse, C; Ladouceur, M, 2008) |
| "Clinical management of warfarin therapy is complex, and dosing algorithms do not include genetic factors or interactions with other drugs for warfarin dose determinations." | 2.73 | Oral anticoagulation with warfarin is significantly influenced by steroids and CYP2C9 polymorphisms in children with cancer. ( Bergan, S; Holmstrøm, H; Ruud, E; Wesenberg, F, 2008) |
| "In a randomized trial of 58 cancer patients receiving strongly emetogenic cytostatic drugs (cisplatin or comparable cytostatic agents, alone or in combination), the anti-emetic action of oral metoclopramide was tested, alone or combined with prednisone." | 2.66 | [Prevention of nausea and emesis during cytostatic therapy. Antiemetic efficacy of high-dosage oral metoclopramide without and with prednisone]. ( Bachmann-Mettler, I; Glaus, A; Köhler, M; Senn, HJ; Weigand, W, 1986) |
| "Treatment of hypercalcemia of malignancy (HCM) is briefly reviewed, available treatments are compared, and treatment guidelines are presented." | 2.41 | Conventional treatment of hypercalcemia of malignancy. ( Davidson, TG, 2001) |
| "Fever, arthritis and skin rash was constant." | 2.41 | [Adult Still's disease: study of a series of 11 cases]. ( Ben Maïz, H; Ben Taarit, C; Turki, S, 2002) |
| "Treatment options for peripheral facial palsy (PFP) are an often discussed problem in neurologic practice." | 2.40 | Peripheral facial palsy: etiology, diagnosis and treatment. ( Fazekas, F; Hartung, HP; Roob, G, 1999) |
| " In terms of reproductive and developmental toxicity, cyclosporine produces some adverse effects in both experimental animals and humans." | 2.39 | International Commission for Protection Against Environmental Mutagens and Carcinogens. Cyclosporine A: review of genotoxicity and potential for adverse human reproductive and developmental effects. Report of a Working Group on the genotoxicity of cyclosp ( Mattison, DR; Olshan, AF; Zwanenburg, TS, 1994) |
| "The results of treatment of advanced histiocytic lymphoma are now approaching the results reported for advanced Hodgkin disease." | 2.36 | Chemotherapy of non-Hodgkin lymphoma: the diffuse types. ( Sweet, DL; Ultmann, JE, 1978) |
| "Charts of 12 298 cancer patients (4499 treated with prednisone equivalents) were analysed descriptively." | 1.91 | Steriod-associated psychiatric burden in cancer patients. ( Euler, S; Günther, MP; Riemann, PM; Schulze, JB; von Känel, R, 2023) |
| "Day-200 nonrelapse mortality (NRM), recurrence or progression of cancer, relapse-related mortality, and overall mortality, adjusted for comorbidity scores, source of donor cells, donor type, patient age, disease severity, conditioning regimen, patient and donor sex, and cytomegalovirus serostatus." | 1.56 | Survival, Nonrelapse Mortality, and Relapse-Related Mortality After Allogeneic Hematopoietic Cell Transplantation: Comparing 2003-2007 Versus 2013-2017 Cohorts. ( Appelbaum, FR; Boeckh, M; Cheng, GS; Deeg, HJ; Flowers, MD; Gooley, TA; Hingorani, S; Lee, SJ; Martin, PJ; McDonald, GB; Mielcarek, M; Pergam, SA; Sandmaier, BM; Schoch, G; Sorror, M; Storb, R, 2020) |
| "Although G-CSF is widely used to prevent or ameliorate leukopenia during cytotoxic chemotherapies, its optimal use is still under debate and depends on many therapy parameters such as dosing and timing of cytotoxic drugs and G-CSF, G-CSF pharmaceuticals used and individual risk factors of patients." | 1.48 | Model-based optimization of G-CSF treatment during cytotoxic chemotherapy. ( Engel, C; Loeffler, M; Loibl, S; Schirm, S; Scholz, M, 2018) |
| "Patients suffering from cancer are often treated with a range of chemotherapeutic agents, but the treatment efficacy varies greatly between patients." | 1.42 | Predicting response to multidrug regimens in cancer patients using cell line experiments and regularised regression models. ( Bødker, JS; Bøgsted, M; Dybkær, K; El-Galaly, TC; Falgreen, S; Johnsen, HE; Kjeldsen, MK; Laursen, MB; Nyegaard, M; Schmitz, A; Xu-Monette, ZY; Young, KH, 2015) |
| "As revealed by network biology, cancers harbor robust biological networks that are inherently resistant to changes, such as those induced by drugs with very narrow mechanisms of action." | 1.40 | Rectifying cancer drug discovery through network pharmacology. ( Azmi, AS; Mohammad, RM, 2014) |
| "Sweet syndrome, also known as acute febrile neutrophilic dermatosis, was diagnosed in two patients." | 1.36 | [Sweet syndrome in underlying malignancy]. ( Dercksen, MW; Nijziel, MR; Prins, M; ten Oever, J; van Hirtum, PV; Vreugdenhil, G, 2010) |
| "The causes of fever in systemic lupus erythematosus (SLE) are complicated." | 1.35 | The causes and clinical significance of fever in systemic lupus erythematosus: a retrospective study of 487 hospitalised patients. ( Yang, CD; Zhou, WJ, 2009) |
| "A link between cancer and limbic encephalitis (LE) has been proposed." | 1.35 | Acute limbic encephalitis: diagnostic and management implications. ( Baxi, S; Lucas-Ramadan, T; Velamoor, R, 2008) |
| "A total of 103 patients with Sweet's syndrome have been seen and treated at Scott and White Memorial Hospital since 1996." | 1.33 | Sweet's syndrome presenting as acute hand infection. ( Bennett, LL; Grothaus, PC; Lynch, DJ; O'Halloran, LE, 2005) |
| "We conclude that women with breast cancer or hematologic malignancy are more likely to develop GI GVHD after autologous transplantation, and that treatment with prednisone was effective." | 1.33 | Gastrointestinal graft-versus-host disease in recipients of autologous hematopoietic stem cells: incidence, risk factors, and outcome. ( Adams, KM; Bensinger, W; Flowers, ME; Gooley, TA; Hockenbery, DM; Holmberg, L; Kikuchi, K; McDonald, GB; Schoch, HG, 2006) |
| "Barriers to using online cancer information are environmental (hardware, connection speeds, time), personal (poor computer literacy and lack of awareness of appropriate sites) and economic (costs of journal subscriptions)." | 1.33 | Information sources used by New South Wales cancer clinicians: a qualitative study. ( Lowinger, JS; Pearson, S-; Ringland, C; Stark, H; Tan, EL; Ward, R, 2006) |
| "A predisposition to developing immune thrombocytopenia (ITP) has not been reported in survivors of childhood cancer." | 1.33 | Immune thrombocytopenia following successful treatment of cancer in children. ( Barnes, C; Blanchette, V; Canning, P; Greenberg, M; Price, V, 2006) |
| "Most anticancer agents act by inducing apoptosis in sensitive tumor cells." | 1.33 | 99mTc-Annexin A5 uptake and imaging to monitor chemosensitivity. ( Belhocine, TZ; Blankenberg, FG, 2005) |
| "The management of cancer in the older aged person is an increasingly common problem." | 1.31 | Management of cancer in the older person: a practical approach. ( Balducci, L; Extermann, M, 2000) |
| "The National Comprehensive Cancer Network (NCCN) of cancer centers has recommended that all patients aged 70 years and older treated with CHOP or cytotoxic chemotherapy of comparable intensity should receive prophylactic G-CSF administration, and that the hemoglobin concentration be maintained at >or=12 g/dl in elderly patients undergoing chemotherapy." | 1.31 | Use of hematopoietic growth factors in elderly patients receiving cytotoxic chemotherapy. ( Bokemeyer, C; Honecker, F; Kolb, G; Lipp, HP; Späth-Schwalbe, E; Wedding, U, 2002) |
| "Dermatomyositis and polymyositis are the two major idiopathic inflammatory myopathies." | 1.31 | [Dermatomyositis and polymyositis: clinical aspects and treatment]. ( Hachulla, E, 2001) |
| "Pancreatitis was found in 51 of 184 (28%) patients at autopsy." | 1.30 | Acute pancreatitis in marrow transplant patients: prevalence at autopsy and risk factor analysis. ( Gooley, T; Hackman, RC; Ko, CW; Lee, SP; McDonald, GB; Myerson, D; Sale, GE; Schoch, HG; Shulman, HM, 1997) |
| "Dermatomyositis is associated with significant morbidity and occasional mortality." | 1.30 | Dermatomyositis: a dermatology-based case series. ( Albertson, D; Dawkins, MA; Hinds, A; Jorizzo, JL; Sinal, SH; Walker, FO, 1998) |
| "A history of preexisting malignancy has been considered a contraindication to cardiac transplantation." | 1.28 | Cardiac transplantation in patients with preexisting malignancies. ( Clark, WR; Dillon, TA; Ladowski, JS; Peterson, AC; Schätzlein, MH; Scheeringa, RH; Sullivan, M, 1991) |
| "Children with malignancy have a high incidence of pneumonia and pneumonitis and death is rare if the patient does not have terminal malignant disease." | 1.28 | Pneumonia and pneumonitis in childhood malignancy. ( Eden, OB; Elton, R; Shaw, NJ, 1992) |
| "Other cancers have about the same-distribution." | 1.28 | Recent contributions to transplantation at the University of Cincinnati. ( Alexander, JW; Bhat, G; Bolce, R; First, MR; Hariharan, S; Munda, R; Penn, I; Ryckman, F; Schroeder, T, 1991) |
| "Three patients with liver cirrhosis showed severe myelosuppression and fever." | 1.28 | [Feasibility of CHOP chemotherapy--with special reference to age, diabetes mellitus, liver cirrhosis and obesity]. ( Fujii, H; Hashimoto, S; Hiramatsu, H; Kondo, M; Kuribayashi, T; Yorozu, A, 1989) |
| "The mechanism of malignancy-associated hypercalcemia includes increased bone resorption and decreased renal calcium clearance which also occur in primary hyperparathyroidism." | 1.28 | Treatment of malignancy-associated hypercalcemia with norethisterone: a case report. ( Anderson, CS; Need, AG; Olweny, CL, 1989) |
| " The side effects of antihistamines are minor, and the dosage of corticosteroid used and length of time it is given are small enough to avoid major side effects." | 1.27 | Chronic urticaria. Possible causes, suggested treatment alternatives. ( Kaplan, AP, 1983) |
| "The example of Hodgkin's lymphoma staging and treatment selection is used." | 1.27 | A decision-analysis methodology for consideration of morbidity factors in clinical decision-making. ( Corder, MP; Ellwein, LB, 1984) |
| "Thirty-four subsequent second malignant neoplasms were observed in 33 patients among those treated for Hodgkin's disease." | 1.27 | Second malignant neoplasms complicating Hodgkin's disease: the National Cancer Institute experience. ( DeVita, VT; Glatstein, E; Kelley, PA; Kinsella, TJ; Makuch, RW; Tester, WJ; Waller, B, 1984) |
| "Secondary tumors were noted in 8 out of 675 patients with Hodgkin's disease during remission following treatment." | 1.27 | [Secondary malignant tumors following treatment of Hodgkin's disease]. ( Shishkin, IP, 1984) |
| "The incidence of a second malignancy has been assessed." | 1.27 | Second malignancy complicating Hodgkin's disease. ( Mercier, JP; Tawil, E, 1983) |
| "Danazol was effective regardless of the severity of the disorder and success or failure of previous treatments." | 1.27 | Danazol therapy for autoimmune hemolytic anemia. ( Ahn, YS; Ayub, J; Harrington, WJ; Mylvaganam, R; Pall, LM, 1985) |
| "Polydermatomyositis is a chronic, non-suppurative disease of the striated muscle." | 1.27 | [Polydermatomyositis in the adult and its management]. ( Albert, J; Lamberti, A; Ott, H; Wauthier, D, 1983) |
| "Frequency of malignancy type (colon seven, lung four, breast three, prostate three, leukemia three, ovary three, stomach two, and lymphoma zero) did not differ significantly from the general population." | 1.27 | Cancer in rheumatoid arthritis: a prospective long-term study of mortality. ( Bloch, D; Fries, JF; Mitchell, DM; Spitz, P, 1985) |
| "ITP was coincident with a diagnosis of cancer (three patients), preceded a diagnosis of cancer (three patients) or followed a diagnosis of cancer (four patients)." | 1.26 | A syndrome resembling idiopathic thrombocytopenic purpura in 10 patients with diverse forms of cancer. ( Boggs, DR; Kim, HD, 1979) |
| "On the other hand, when a neoplasm was present, the course of the disease was satisfactorily modified only after the extirpation of the neoplasm." | 1.26 | [Immunologic studies in polymyositis syndromes]. ( Casanova, E; Lasalvia, E; Oehninger, C; Paciel, J; Passano, R; Rodríguez, T, 1979) |
| "The patient had histamine-fast achlorhydria and a normal gastric biopsy and no gastrin was recovered from the tumour tissue." | 1.24 | WATERY DIARRHOEA AND AN ISLET CELL TUMOUR. ( CREAMER, B; HINDLE, W; MCBRIEN, DJ, 1964) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 232 (72.50) | 18.7374 |
| 1990's | 24 (7.50) | 18.2507 |
| 2000's | 32 (10.00) | 29.6817 |
| 2010's | 21 (6.56) | 24.3611 |
| 2020's | 11 (3.44) | 2.80 |
| Authors | Studies |
|---|---|
| Tukey, RH | 1 |
| Strassburg, CP | 1 |
| Lin, R | 1 |
| Elf, S | 1 |
| Shan, C | 1 |
| Kang, HB | 1 |
| Ji, Q | 1 |
| Zhou, L | 1 |
| Hitosugi, T | 1 |
| Zhang, L | 3 |
| Zhang, S | 1 |
| Seo, JH | 1 |
| Xie, J | 1 |
| Tucker, M | 1 |
| Gu, TL | 1 |
| Sudderth, J | 1 |
| Jiang, L | 1 |
| Mitsche, M | 1 |
| DeBerardinis, RJ | 1 |
| Wu, S | 1 |
| Li, Y | 2 |
| Mao, H | 1 |
| Chen, PR | 1 |
| Wang, D | 1 |
| Chen, GZ | 1 |
| Hurwitz, SJ | 1 |
| Lonial, S | 1 |
| Arellano, ML | 1 |
| Khoury, HJ | 1 |
| Khuri, FR | 1 |
| Lee, BH | 1 |
| Lei, Q | 1 |
| Brat, DJ | 1 |
| Ye, K | 1 |
| Boggon, TJ | 1 |
| He, C | 1 |
| Kang, S | 1 |
| Fan, J | 1 |
| Chen, J | 1 |
| Kaviani, A | 1 |
| Khansari Nejad, N | 1 |
| Akour, A | 1 |
| AlMuhaissen, SA | 1 |
| Nusair, MB | 1 |
| Al-Tammemi, AB | 1 |
| Mahmoud, NN | 1 |
| Jalouqa, S | 1 |
| Alrawashdeh, MN | 1 |
| Shanahan, JP | 1 |
| Moore, CM | 1 |
| Kampf, JW | 1 |
| Szymczak, NK | 1 |
| Guo, J | 1 |
| Wang, H | 1 |
| Luo, Y | 1 |
| An, H | 1 |
| Zhang, Z | 2 |
| Liu, G | 1 |
| Li, J | 2 |
| Metcalfe, GD | 1 |
| Smith, TW | 1 |
| Hippler, M | 1 |
| Ayala Izurieta, JE | 1 |
| Márquez, CO | 1 |
| García, VJ | 1 |
| Jara Santillán, CA | 1 |
| Sisti, JM | 1 |
| Pasqualotto, N | 1 |
| Van Wittenberghe, S | 1 |
| Delegido, J | 1 |
| Kubo, Y | 1 |
| Kitagawa, Y | 1 |
| Miyazaki, T | 1 |
| Sohda, M | 1 |
| Yamaji, T | 1 |
| Sakai, M | 1 |
| Saeki, H | 1 |
| Nemoto, K | 1 |
| Oyama, T | 2 |
| Muto, M | 1 |
| Takeuchi, H | 1 |
| Toh, Y | 1 |
| Matsubara, H | 1 |
| Mano, M | 1 |
| Kono, K | 1 |
| Kato, K | 1 |
| Yoshida, M | 1 |
| Kawakubo, H | 1 |
| Booka, E | 1 |
| Yamatsuji, T | 1 |
| Kato, H | 1 |
| Ito, Y | 1 |
| Ishikawa, H | 1 |
| Ishihara, R | 1 |
| Tsushima, T | 1 |
| Kawachi, H | 1 |
| Kojima, T | 1 |
| Kuribayashi, S | 1 |
| Makino, T | 1 |
| Matsuda, S | 1 |
| Doki, Y | 1 |
| Ma, P | 1 |
| Tang, X | 1 |
| Wang, X | 4 |
| Wang, W | 1 |
| Zhang, X | 2 |
| Wang, S | 2 |
| Zhou, N | 1 |
| Dodd, J | 1 |
| Jordan, R | 1 |
| Makhlina, M | 1 |
| Pesco Koplowitz, L | 1 |
| Koplowitz, B | 1 |
| Barnett, K | 1 |
| Yang, WH | 1 |
| Spana, C | 1 |
| Buchanan, SW | 1 |
| Mafa-Attoye, T | 1 |
| Dunfield, K | 1 |
| Thevathasan, NV | 1 |
| Isaac, ME | 1 |
| Wu, X | 3 |
| Huang, JW | 1 |
| Su, BK | 1 |
| Yuan, L | 1 |
| Zheng, WQ | 1 |
| Zhang, H | 3 |
| Zheng, YX | 1 |
| Zhu, W | 1 |
| Chou, PT | 1 |
| Manso, AP | 1 |
| De Morais, DC | 1 |
| Yamamoto, K | 1 |
| Owen, G | 1 |
| de Carvalho, RM | 1 |
| Palma-Dibb, RG | 1 |
| Brown, JC | 1 |
| Yang, S | 1 |
| Mire, EF | 1 |
| Miele, L | 1 |
| Ochoa, A | 1 |
| Zabaleta, J | 1 |
| Katzmarzyk, PT | 1 |
| Moi, CT | 1 |
| Bhowmick, S | 1 |
| Qureshi, M | 1 |
| Wang, K | 1 |
| Feng, B | 1 |
| Yang, Y | 2 |
| Chen, Y | 1 |
| Wang, Y | 3 |
| Yang, L | 1 |
| Jiang, K | 1 |
| James, TD | 1 |
| Chaturvedi, V | 1 |
| Postiglione, WM | 1 |
| Chakraborty, RD | 1 |
| Yu, B | 1 |
| Tabiś, W | 1 |
| Hameed, S | 1 |
| Biniskos, N | 1 |
| Jacobson, A | 1 |
| Zhou, H | 1 |
| Greven, M | 1 |
| Ferry, VE | 1 |
| Leighton, C | 1 |
| Wu, F | 1 |
| Lei, H | 1 |
| Chen, G | 1 |
| Chen, C | 1 |
| Song, Y | 1 |
| Cao, Z | 1 |
| Zhang, C | 2 |
| Zhou, J | 2 |
| Lu, Y | 1 |
| Pappone, C | 1 |
| Santinelli, V | 1 |
| Mecarocci, V | 1 |
| Tondi, L | 1 |
| Ciconte, G | 1 |
| Manguso, F | 1 |
| Sturla, F | 1 |
| Vicedomini, G | 1 |
| Micaglio, E | 1 |
| Anastasia, L | 1 |
| Pica, S | 1 |
| Camporeale, A | 1 |
| Lombardi, M | 1 |
| Shieh, PB | 1 |
| Elfring, G | 1 |
| Trifillis, P | 1 |
| Santos, C | 1 |
| Peltz, SW | 1 |
| Parsons, JA | 1 |
| Apkon, S | 1 |
| Darras, BT | 1 |
| Campbell, C | 1 |
| McDonald, CM | 1 |
| Galaviz, KI | 1 |
| Shah, NS | 1 |
| Gutierrez, M | 1 |
| Collins, LF | 1 |
| Lahiri, CD | 1 |
| Moran, CA | 1 |
| Szabo, B | 1 |
| Sumitani, J | 1 |
| Rhodes, J | 1 |
| Marconi, VC | 1 |
| Nguyen, ML | 1 |
| Cantos, VD | 1 |
| Armstrong, WS | 1 |
| Colasanti, JA | 1 |
| Choudhury, AD | 1 |
| Higano, CS | 1 |
| de Bono, JS | 1 |
| Cook, N | 1 |
| Rathkopf, DE | 1 |
| Wisinski, KB | 1 |
| Martin-Liberal, J | 1 |
| Linch, M | 1 |
| Heath, EI | 1 |
| Baird, RD | 1 |
| García-Carbacho, J | 1 |
| Quintela-Fandino, M | 1 |
| Barry, ST | 1 |
| de Bruin, EC | 1 |
| Colebrook, S | 1 |
| Hawkins, G | 1 |
| Klinowska, T | 1 |
| Maroj, B | 1 |
| Moorthy, G | 1 |
| Mortimer, PG | 1 |
| Moschetta, M | 1 |
| Nikolaou, M | 1 |
| Sainsbury, L | 1 |
| Shapiro, GI | 1 |
| Siu, LL | 1 |
| Hansen, AR | 1 |
| Benarous, X | 1 |
| Brocheton, C | 1 |
| Bonnay, C | 1 |
| Boissel, L | 1 |
| Crovetto, C | 1 |
| Lahaye, H | 1 |
| Guilé, JM | 1 |
| Theret, P | 1 |
| Gondry, J | 1 |
| Foulon, A | 1 |
| Kim, E | 1 |
| Yoo, SH | 1 |
| Chen, Z | 1 |
| Sousa, JA | 1 |
| Batista, E | 1 |
| Demeyer, S | 1 |
| Fischer, N | 1 |
| Pellegrino, O | 1 |
| Ribeiro, AS | 1 |
| Martins, LL | 1 |
| Worthy, FR | 1 |
| Goldberg, SD | 1 |
| Ranjitkar, S | 1 |
| Xu, JC | 1 |
| Asmara, AAGY | 1 |
| Karna, MB | 1 |
| Meregawa, PF | 1 |
| Deslivia, MF | 1 |
| Carula, BC | 1 |
| Giostri, GS | 1 |
| Bebber, F | 1 |
| Batista, MFDS | 1 |
| Silva, FBD | 1 |
| Novak, EM | 1 |
| Vilela, JCS | 1 |
| Franco, N | 1 |
| Campos, G | 1 |
| Deligne, LM | 1 |
| Machado, TLA | 1 |
| Degasperi, FA | 1 |
| Scatigna, BF | 1 |
| Falótico, GG | 1 |
| Romero, V | 1 |
| Basile, R | 1 |
| Takata, ET | 1 |
| Kaleka, CC | 1 |
| Debieux, P | 1 |
| Antonioli, E | 1 |
| Zucconi, E | 1 |
| Cohen, M | 3 |
| Ferretti, M | 1 |
| Bampidis, V | 2 |
| Azimonti, G | 2 |
| Bastos, ML | 2 |
| Christensen, H | 2 |
| Fašmon Durjava, M | 2 |
| Kouba, M | 2 |
| López-Alonso, M | 2 |
| López Puente, S | 2 |
| Marcon, F | 2 |
| Mayo, B | 2 |
| Pechová, A | 2 |
| Petkova, M | 2 |
| Ramos, F | 2 |
| Sanz, Y | 2 |
| Villa, RE | 2 |
| Woutersen, R | 2 |
| Brantom, P | 2 |
| Chesson, A | 2 |
| Westendorf, J | 2 |
| Manini, P | 2 |
| Pizzo, F | 2 |
| Dusemund, B | 2 |
| Aron, J | 1 |
| Albert, PS | 1 |
| Gribble, MO | 1 |
| Samankul, A | 1 |
| Senawong, G | 1 |
| Swatsitang, P | 1 |
| Sripa, B | 1 |
| Phaosiri, C | 1 |
| Kanokmedhakul, S | 1 |
| Senawong, T | 1 |
| Sirajudeen, MS | 1 |
| Alzhrani, M | 1 |
| Alanazi, A | 1 |
| Alqahtani, M | 1 |
| Waly, M | 1 |
| Unnikrishnan, R | 1 |
| Muthusamy, H | 1 |
| Alrubaia, W | 1 |
| Alanazi, N | 1 |
| Seyam, MK | 1 |
| Kashoo, F | 1 |
| Miraj, M | 1 |
| Channmgere Govindappa, S | 1 |
| Alghamdi, KA | 1 |
| Al-Hussinan, NM | 1 |
| Wang, Z | 2 |
| Qu, T | 1 |
| Qi, H | 1 |
| Zhao, S | 1 |
| Shi, H | 2 |
| Bai, W | 1 |
| Yu, Y | 1 |
| Zhao, P | 1 |
| Yakubov, S | 1 |
| Stockerl, WJ | 1 |
| Tian, X | 1 |
| Shahin, A | 1 |
| Mandigma, MJP | 1 |
| Gschwind, RM | 1 |
| Barham, JP | 1 |
| Li, R | 1 |
| Jiang, D | 1 |
| Du, P | 1 |
| Yuan, C | 1 |
| Cui, X | 1 |
| Tang, Q | 1 |
| Zheng, J | 1 |
| Lu, K | 1 |
| Ren, X | 1 |
| Gao, S | 1 |
| Zhan, X | 1 |
| Ramgoolam, KH | 1 |
| Dolphin, AC | 1 |
| Shi, Q | 1 |
| Zhou, YJ | 1 |
| Fang, JG | 1 |
| Zhong, X | 1 |
| Chen, LZ | 1 |
| Hou, HZ | 1 |
| Ma, L | 1 |
| Feng, SZ | 1 |
| He, JW | 1 |
| Huang, R | 1 |
| Wang, YF | 1 |
| Guo, FL | 1 |
| Li, LJ | 2 |
| Ruan, XH | 2 |
| Fu, GM | 1 |
| Zhao, JZ | 2 |
| Hou, XK | 1 |
| Gao, M | 2 |
| Zheng, XQ | 2 |
| Zeng, Y | 1 |
| Huang, DM | 1 |
| Zhang, JM | 1 |
| Kang, M | 1 |
| Zhu, J | 1 |
| Xu, YJ | 1 |
| Li, SN | 1 |
| Lai, JM | 1 |
| Liu, JJ | 1 |
| Wen, S | 1 |
| Yan, HH | 1 |
| Cheng, R | 1 |
| Zhu, F | 1 |
| Gao, PF | 1 |
| Zou, HY | 1 |
| Huang, CZ | 1 |
| Wang, J | 1 |
| AbdElgawad, H | 1 |
| Zinta, G | 1 |
| Hornbacher, J | 1 |
| Papenbrock, J | 1 |
| Markakis, MN | 1 |
| Asard, H | 1 |
| Beemster, GTS | 1 |
| Fukushi, Y | 1 |
| Akamine, Y | 1 |
| Abumiya, M | 1 |
| Tozawa, N | 1 |
| Yamashita, T | 1 |
| Nara, M | 1 |
| Kameoka, Y | 1 |
| Takahashi, N | 1 |
| Miura, M | 1 |
| Qi, G | 1 |
| Yu, T | 1 |
| Guo, Z | 1 |
| Ma, K | 1 |
| Jin, Y | 1 |
| Lucon-Xiccato, T | 1 |
| Montalbano, G | 1 |
| Gatto, E | 1 |
| Frigato, E | 1 |
| D'Aniello, S | 1 |
| Bertolucci, C | 1 |
| Shi, W | 1 |
| Ge, N | 1 |
| Yu, S | 1 |
| Wu, J | 1 |
| Hu, T | 1 |
| Wei, J | 1 |
| Yan, X | 1 |
| Lin, K | 1 |
| Deng, T | 1 |
| Qu, H | 1 |
| Ou, H | 1 |
| Huang, Q | 1 |
| Gao, B | 1 |
| Li, X | 1 |
| Wei, N | 1 |
| von Haeften, K | 1 |
| Laarmann, T | 1 |
| Wabnitz, H | 1 |
| Möller, T | 1 |
| Gries, KJ | 1 |
| Hart, CR | 1 |
| Kunz, HE | 1 |
| Ryan, Z | 1 |
| Parvizi, M | 1 |
| Liu, Y | 2 |
| Dasari, S | 1 |
| Lanza, IR | 1 |
| Perez, HL | 1 |
| Andonian, C | 1 |
| Wan, KX | 1 |
| Potts, D | 1 |
| Gonzalez, P | 1 |
| Smith, I | 1 |
| Kavetska, O | 1 |
| Günther, MP | 1 |
| Riemann, PM | 1 |
| von Känel, R | 1 |
| Euler, S | 1 |
| Schulze, JB | 1 |
| McDonald, GB | 3 |
| Sandmaier, BM | 1 |
| Mielcarek, M | 1 |
| Sorror, M | 1 |
| Pergam, SA | 1 |
| Cheng, GS | 1 |
| Hingorani, S | 1 |
| Boeckh, M | 1 |
| Flowers, MD | 1 |
| Lee, SJ | 1 |
| Appelbaum, FR | 1 |
| Storb, R | 2 |
| Martin, PJ | 1 |
| Deeg, HJ | 1 |
| Schoch, G | 1 |
| Gooley, TA | 2 |
| Jurczak, W | 1 |
| Długosz-Danecka, M | 1 |
| Szmit, S | 1 |
| Azaro, A | 1 |
| Baldini, C | 1 |
| Rodon, J | 1 |
| Soria, JC | 1 |
| Yuen, E | 1 |
| Lithio, A | 1 |
| Oakley, G | 1 |
| Benhadji, KA | 1 |
| Massard, C | 1 |
| Suyama, T | 1 |
| Yui, T | 1 |
| Horiuchi, A | 1 |
| Irie, R | 1 |
| Osamura, Y | 1 |
| Miyao, N | 1 |
| Giulino-Roth, L | 1 |
| Pei, Q | 1 |
| Buxton, A | 1 |
| Bush, R | 1 |
| Wu, Y | 1 |
| Wolden, SL | 1 |
| Constine, LS | 1 |
| Kelly, KM | 1 |
| Schwartz, CL | 1 |
| Friedman, DL | 1 |
| Bermas, BL | 1 |
| Zaha, VG | 1 |
| Khan, N | 1 |
| Pernes, T | 1 |
| Weiss, A | 1 |
| Trivedi, C | 1 |
| Patel, M | 1 |
| Xie, D | 1 |
| Yang, YX | 1 |
| Martin, AL | 1 |
| Frank, JP | 1 |
| Waggoner, ML | 1 |
| Schirm, S | 1 |
| Engel, C | 1 |
| Loibl, S | 1 |
| Loeffler, M | 1 |
| Scholz, M | 1 |
| Maliszewska, O | 1 |
| Plenis, A | 1 |
| Olędzka, I | 1 |
| Kowalski, P | 1 |
| Miękus, N | 1 |
| Bień, E | 1 |
| Krawczyk, MA | 1 |
| Adamkiewicz-Drożynska, E | 1 |
| Bączek, T | 1 |
| Ma, C | 1 |
| Hodi, FS | 1 |
| Giobbie-Hurder, A | 1 |
| Zhang, A | 1 |
| Zhou, Y | 1 |
| Mao, F | 1 |
| Angell, TE | 1 |
| Andrews, CP | 1 |
| Hu, J | 1 |
| Barroso-Sousa, R | 1 |
| Kaiser, UB | 1 |
| Tolaney, SM | 1 |
| Min, L | 1 |
| Corsello, SM | 1 |
| Salvatori, R | 1 |
| Barnabei, A | 1 |
| De Vecchis, L | 1 |
| Marchetti, P | 1 |
| Torino, F | 1 |
| MARTINEZDIAZ, J | 1 |
| Tefferi, A | 2 |
| Hudgens, S | 1 |
| Mesa, R | 1 |
| Gale, RP | 1 |
| Verstovsek, S | 1 |
| Passamonti, F | 1 |
| Cervantes, F | 1 |
| Rivera, C | 1 |
| Tencer, T | 1 |
| Khan, ZM | 1 |
| Azmi, AS | 1 |
| Mohammad, RM | 1 |
| Bichile, T | 1 |
| Petri, M | 1 |
| Tan, P | 1 |
| Taylor, G | 1 |
| Thiessen, R | 1 |
| Beckert, L | 1 |
| Fan, H | 1 |
| Lu, X | 1 |
| Guo, B | 1 |
| Zhang, Y | 2 |
| Zhang, W | 1 |
| Nie, J | 1 |
| Feng, K | 1 |
| Chen, M | 1 |
| Shi, F | 1 |
| Fu, X | 1 |
| Zhu, H | 1 |
| Han, W | 1 |
| Falgreen, S | 1 |
| Dybkær, K | 1 |
| Young, KH | 1 |
| Xu-Monette, ZY | 1 |
| El-Galaly, TC | 1 |
| Laursen, MB | 1 |
| Bødker, JS | 1 |
| Kjeldsen, MK | 1 |
| Schmitz, A | 1 |
| Nyegaard, M | 1 |
| Johnsen, HE | 1 |
| Bøgsted, M | 1 |
| Bravo-Oro, A | 1 |
| Acosta-Yebra, D | 1 |
| Grimaldo-Zapata, IP | 1 |
| Reyes-Vaca, G | 1 |
| Riu, G | 1 |
| Gaba, L | 1 |
| Victoria, I | 1 |
| Molas, G | 1 |
| do Pazo, F | 1 |
| Gómez, B | 1 |
| Creus, N | 1 |
| Vidal, L | 1 |
| Salt, E | 1 |
| Wiggins, AT | 1 |
| Rayens, MK | 1 |
| Morris, BJ | 1 |
| Mannino, D | 1 |
| Hoellein, A | 1 |
| Donegan, RP | 1 |
| Crofford, LJ | 1 |
| Floeter, AE | 1 |
| Patel, A | 1 |
| Tran, M | 1 |
| Chamberlain, MC | 1 |
| Hendrie, PC | 1 |
| Gopal, AK | 1 |
| Cassaday, RD | 1 |
| Roufosse, F | 1 |
| Cogan, E | 1 |
| Kneba, M | 1 |
| Schrader, C | 1 |
| Köhne, H | 1 |
| Cantarovich, M | 1 |
| Durrbach, A | 1 |
| Hiesse, C | 1 |
| Ladouceur, M | 1 |
| Benoit, G | 1 |
| Charpentier, B | 1 |
| Zhou, WJ | 1 |
| Yang, CD | 1 |
| Kummar, S | 1 |
| Gutierrez, ME | 1 |
| Gardner, ER | 1 |
| Figg, WD | 1 |
| Melillo, G | 1 |
| Dancey, J | 1 |
| Sausville, EA | 1 |
| Conley, BA | 1 |
| Murgo, AJ | 1 |
| Doroshow, JH | 1 |
| Stone, JH | 1 |
| Merkel, PA | 1 |
| Spiera, R | 1 |
| Seo, P | 1 |
| Langford, CA | 1 |
| Hoffman, GS | 1 |
| Kallenberg, CG | 1 |
| St Clair, EW | 1 |
| Turkiewicz, A | 1 |
| Tchao, NK | 1 |
| Webber, L | 1 |
| Ding, L | 1 |
| Sejismundo, LP | 1 |
| Mieras, K | 1 |
| Weitzenkamp, D | 1 |
| Ikle, D | 1 |
| Seyfert-Margolis, V | 1 |
| Mueller, M | 1 |
| Brunetta, P | 1 |
| Allen, NB | 1 |
| Fervenza, FC | 1 |
| Geetha, D | 1 |
| Keogh, KA | 1 |
| Kissin, EY | 1 |
| Monach, PA | 1 |
| Peikert, T | 1 |
| Stegeman, C | 1 |
| Ytterberg, SR | 1 |
| Specks, U | 1 |
| van Hirtum, PV | 1 |
| Prins, M | 1 |
| ten Oever, J | 1 |
| Nijziel, MR | 1 |
| Vreugdenhil, G | 1 |
| Dercksen, MW | 1 |
| Moragrega, B | 1 |
| Dolz, R | 1 |
| López Alejandre, I | 1 |
| Núñez Sánchez, A | 1 |
| Chu, DT | 1 |
| Salvatore, JR | 1 |
| Harrington, J | 1 |
| Kummet, T | 1 |
| MONTORSI, W | 1 |
| VILLA, L | 1 |
| OSELLADORE, G | 1 |
| MAGRASSI, F | 1 |
| CONSOLI, G | 1 |
| PESCETTO, G | 2 |
| MICHEL, PJ | 2 |
| MOESCHLIN, S | 3 |
| THALMANN, A | 2 |
| TRAISSAC, FJ | 1 |
| MOULINIER, J | 1 |
| DUPUY, P | 1 |
| COSTE, F | 1 |
| CAYLA, J | 1 |
| SIGWALD, J | 1 |
| DE AJURIAGUERRA, J | 1 |
| BOUTTIER, D | 1 |
| DUBOIS-FERRIERE, H | 1 |
| BROCARD, H | 1 |
| CHOFFEL, C | 1 |
| GUIBE, C | 1 |
| GATTI, E | 1 |
| SFONDRINI, G | 1 |
| BORGHETT, U | 1 |
| MALTBY, EJ | 1 |
| LAIDLAW, JC | 1 |
| PIREDDA, G | 1 |
| GORSUCH, GE | 1 |
| FRANCO, J | 1 |
| HALL, BE | 1 |
| HALES, DR | 1 |
| SCHOYER, NH | 1 |
| NOCCA, G | 1 |
| COTTINI, E | 1 |
| ALAJOUANINE, T | 1 |
| NEHLIL, J | 1 |
| CONTAMIN, F | 1 |
| CATHALA, HP | 1 |
| PANOS, TC | 1 |
| POTH, EJ | 1 |
| BOCCI, F | 1 |
| DZIUBA, K | 1 |
| BOURGEOIS, J | 1 |
| GODLEWSKI, JL | 1 |
| VIALA, C | 1 |
| GARDNER, B | 3 |
| GORDAN, GS | 3 |
| LOKEN, HF | 1 |
| THOMAS, AN | 2 |
| SKOOG, WA | 1 |
| ADAMS, WS | 1 |
| LANGNICKEL, D | 1 |
| HAAS, E | 1 |
| HARTAI, F | 1 |
| FRITZSCHE, D | 1 |
| RIETSCHEL, HG | 1 |
| JADRESIC, A | 1 |
| PABST, I | 1 |
| LAZO, M | 1 |
| BIERMAN, HR | 1 |
| WITT, JA | 1 |
| GRAHAM, WP | 2 |
| KELLY, M | 1 |
| SCHMIDT, E | 1 |
| SCHMIDT, FW | 1 |
| KATCHMAN, BJ | 1 |
| ZIPF, RE | 1 |
| MURPHY, JP | 1 |
| RANLOV, P | 1 |
| VIDEBAEK, A | 2 |
| PEARSON, CM | 2 |
| WILTSHAW, E | 1 |
| MARTZ, G | 1 |
| REISMAN, LE | 1 |
| MITANI, M | 1 |
| ZUELZER, WW | 1 |
| ERIKSEN, KR | 1 |
| HOJGAARD, K | 1 |
| FAYOS, JV | 1 |
| NIZET, A | 1 |
| MILLER, DJ | 1 |
| SCHOEN, D | 1 |
| FEINE, U | 1 |
| BENNINGHOFF, D | 1 |
| ROBBINS, R | 1 |
| HOFFBRAND, BI | 1 |
| IRVINE, RA | 1 |
| ROBERTSON, WB | 1 |
| BOOTSMA, BK | 2 |
| SULLI, G | 1 |
| NISSEN-MEYER, R | 2 |
| VERHAEGHE, A | 1 |
| ROBERTD ESHOUGUES, J | 1 |
| LEBEURRE, R | 1 |
| LESAGE, R | 1 |
| BISERTE, G | 1 |
| HAVEZ, R | 1 |
| CARIDROIT, M | 1 |
| CHEN, KP | 1 |
| CHU, CP | 1 |
| TANG, CS | 1 |
| CHANG, FL | 1 |
| KARNOFSKY, DA | 1 |
| DEBLASIIS, M | 1 |
| DIETZSCH, HJ | 1 |
| LIBERTI, R | 1 |
| OTA, K | 1 |
| COWLING, DC | 1 |
| QUAGLINO, D | 1 |
| HAYHOE, FG | 1 |
| SHIMIZU, J | 2 |
| KOBAYASHI, J | 2 |
| OTA, T | 2 |
| YOSHIDA, H | 2 |
| FUJII, H | 3 |
| SAKAKIBARA, N | 2 |
| ARIMASA, S | 2 |
| GASSER, C | 1 |
| WOODLIFF, HJ | 1 |
| KAKULAS, BA | 1 |
| NELSON, RS | 1 |
| DEELIZALDE, R | 1 |
| FRENKEL, M | 1 |
| SCHWARZ, F | 1 |
| KUIPERS, T | 1 |
| LOKKERBOL, H | 1 |
| HOUTZAGERS, JJ | 1 |
| OUGIER, J | 1 |
| COPFERMAN, R | 1 |
| MENGUS, C | 1 |
| MCANDREW, GM | 1 |
| GACON, G | 1 |
| PAPILLON, J | 1 |
| PADER, E | 1 |
| KIRSCHNER, PA | 1 |
| GREENSPAN, EM | 1 |
| EAKINS, D | 1 |
| FULTON, T | 1 |
| HADDEN, DR | 1 |
| HINDLE, W | 1 |
| MCBRIEN, DJ | 1 |
| CREAMER, B | 1 |
| BODEY, GP | 1 |
| NIES, BA | 1 |
| MOHBERG, NR | 1 |
| FREOREOCJ, EJ | 1 |
| KENNEDY, BJ | 1 |
| LOEHRY, CA | 1 |
| CHEEVER, AW | 1 |
| VALSAMIS, MP | 1 |
| RABSON, AS | 1 |
| EVANS, FJ | 1 |
| HILTON, JH | 1 |
| DUMA, RJ | 1 |
| BOYETT, JD | 1 |
| BEETHAM, WP | 1 |
| BERNARD, J | 1 |
| BOIRON, M | 1 |
| MANUS, A | 1 |
| LEVY, JP | 1 |
| BRIERE, J | 1 |
| DUMONT, J | 1 |
| RIECHE, K | 1 |
| GOFFRINI, P | 1 |
| HYMAN, CB | 1 |
| BOGLE, JM | 1 |
| BRUBAKER, CA | 1 |
| WILLIAMS, K | 1 |
| HAMMOND, D | 1 |
| KASTIN, AJ | 1 |
| LIPSETT, MB | 1 |
| OMMAYA, AK | 1 |
| MOSER, JM | 1 |
| D ANGIO, GJ | 1 |
| MIUS, A | 1 |
| EVANS, AE | 1 |
| EDWARDS, CL | 1 |
| GENGOZIAN, N | 1 |
| RUDERMAN, NB | 1 |
| HALL, TC | 1 |
| GARVIE, WH | 1 |
| LUPOVITCH, A | 1 |
| KATASE, RY | 1 |
| RANDALL, HP | 1 |
| BELLAMY, MD | 1 |
| GOLDMAN, BS | 1 |
| PEARSON, FG | 1 |
| MARTIN, DC | 1 |
| RUBINI, M | 1 |
| ROSEN, VJ | 1 |
| MANNHEIMER, IH | 1 |
| JIJI, RM | 1 |
| SACKS, MS | 1 |
| LINBERG, EJ | 1 |
| SPURLING, CL | 1 |
| DAMESHEK, W | 1 |
| NECHELES, TF | 1 |
| FINKEL, HE | 1 |
| ALLEN, DM | 1 |
| SACREZ, R | 1 |
| PAIRA, M | 1 |
| FRENZEL, J | 1 |
| KLUST, E | 1 |
| GALTON, DA | 1 |
| JORGSHOLM, B | 1 |
| NEWTON, JT | 1 |
| Miller, OF | 1 |
| Smith, LJ | 1 |
| Ferrara, EX | 1 |
| McAleer, IM | 1 |
| Kaplan, GW | 1 |
| Fortner, BV | 1 |
| Schwartzberg, L | 1 |
| Tauer, K | 1 |
| Houts, AC | 1 |
| Hackett, J | 1 |
| Stolshek, BS | 1 |
| Price, V | 1 |
| Barnes, C | 1 |
| Canning, P | 1 |
| Blanchette, V | 1 |
| Greenberg, M | 1 |
| Belhocine, TZ | 1 |
| Blankenberg, FG | 1 |
| O'Halloran, LE | 1 |
| Bennett, LL | 1 |
| Grothaus, PC | 1 |
| Lynch, DJ | 1 |
| Holmberg, L | 1 |
| Kikuchi, K | 1 |
| Adams, KM | 1 |
| Hockenbery, DM | 1 |
| Flowers, ME | 1 |
| Schoch, HG | 2 |
| Bensinger, W | 1 |
| Yakupoglu, YK | 1 |
| Buell, JF | 1 |
| Woodle, S | 1 |
| Kahan, BD | 1 |
| Jones, JA | 1 |
| Avritscher, EB | 1 |
| Cooksley, CD | 1 |
| Michelet, M | 1 |
| Bekele, BN | 1 |
| Elting, LS | 1 |
| Tan, EL | 1 |
| Stark, H | 1 |
| Lowinger, JS | 1 |
| Ringland, C | 1 |
| Ward, R | 1 |
| Pearson, S- | 1 |
| Ruud, E | 1 |
| Holmstrøm, H | 1 |
| Bergan, S | 1 |
| Wesenberg, F | 1 |
| Trappe, R | 1 |
| Riess, H | 2 |
| Babel, N | 1 |
| Hummel, M | 1 |
| Lehmkuhl, H | 2 |
| Jonas, S | 2 |
| Anagnostopoulos, I | 2 |
| Papp-Vary, M | 1 |
| Reinke, P | 2 |
| Hetzer, R | 2 |
| Dörken, B | 2 |
| Oertel, S | 2 |
| Hartman, A | 1 |
| van den Bos, C | 1 |
| Stijnen, T | 1 |
| Pieters, R | 1 |
| Taskinen, M | 2 |
| Karjalainen-Lindsberg, ML | 2 |
| Nyman, H | 1 |
| Eerola, LM | 1 |
| Leppä, S | 2 |
| Trappe, RU | 1 |
| Choquet, S | 1 |
| Dreyling, M | 1 |
| Mergenthaler, HG | 1 |
| Jäger, U | 1 |
| Kebelmann-Betzing, C | 1 |
| Leblond, V | 1 |
| Lucas-Ramadan, T | 1 |
| Baxi, S | 1 |
| Velamoor, R | 1 |
| Haberal, MA | 1 |
| Kaplan, AP | 1 |
| Bidet, JM | 1 |
| Ferriere, JP | 1 |
| Besse, G | 1 |
| Chollet, P | 1 |
| Gaillard, G | 1 |
| Plagne, R | 1 |
| Moser, K | 1 |
| Pohl, A | 1 |
| Albert, J | 1 |
| Lamberti, A | 1 |
| Ott, H | 1 |
| Wauthier, D | 1 |
| Sumi, SM | 1 |
| Farrell, DF | 1 |
| Knauss, TA | 1 |
| Senn, HJ | 2 |
| Glaus, A | 2 |
| Bachmann-Mettler, I | 2 |
| Corder, MP | 1 |
| Ellwein, LB | 1 |
| Tester, WJ | 1 |
| Kinsella, TJ | 1 |
| Waller, B | 1 |
| Makuch, RW | 1 |
| Kelley, PA | 1 |
| Glatstein, E | 1 |
| DeVita, VT | 4 |
| Shishkin, IP | 1 |
| Berliner, S | 1 |
| Shoenfeld, Y | 1 |
| Sidi, Y | 1 |
| Santo, M | 1 |
| Weinberger, A | 1 |
| Luria, D | 1 |
| Hazaz, B | 1 |
| Pecht, M | 1 |
| Zaizov, R | 1 |
| Pinkhas, J | 1 |
| Tawil, E | 1 |
| Mercier, JP | 1 |
| Hill, CA | 1 |
| Cangir, A | 1 |
| Sullivan, MP | 2 |
| Barousse, AP | 1 |
| Costa, JA | 1 |
| Eposto, M | 1 |
| Laplume, H | 1 |
| Segura, EL | 1 |
| Penn, I | 3 |
| Rosenthal, RC | 1 |
| Clare, MG | 1 |
| Blain, E | 1 |
| Taylor, JH | 1 |
| Read, NW | 1 |
| Read, MG | 1 |
| Krejs, GJ | 1 |
| Hendler, RS | 1 |
| Davis, G | 1 |
| Fordtran, JS | 1 |
| Stehbens, JA | 1 |
| Ford, ME | 1 |
| Kisker, CT | 1 |
| Clarke, WR | 1 |
| Strayer, F | 1 |
| Binstock, ML | 1 |
| Mundy, GR | 1 |
| Fraser, AD | 1 |
| Olshan, AF | 1 |
| Mattison, DR | 1 |
| Zwanenburg, TS | 1 |
| Sørensen, JB | 1 |
| Holtgrave, EA | 1 |
| Heinze, F | 1 |
| Henze, G | 1 |
| Smith, DC | 1 |
| Trump, DL | 1 |
| Dhodapkar, MV | 1 |
| Li, CY | 1 |
| Lust, JA | 1 |
| Phyliky, RL | 1 |
| Sheil, AG | 1 |
| Disney, AP | 1 |
| Mathew, TH | 1 |
| Amiss, N | 1 |
| Daly, EF | 1 |
| Kubiak, NT | 1 |
| McMurray, R | 1 |
| Ko, CW | 1 |
| Gooley, T | 1 |
| Myerson, D | 1 |
| Hackman, RC | 1 |
| Shulman, HM | 1 |
| Sale, GE | 1 |
| Lee, SP | 1 |
| Dawkins, MA | 1 |
| Jorizzo, JL | 1 |
| Walker, FO | 1 |
| Albertson, D | 1 |
| Sinal, SH | 1 |
| Hinds, A | 1 |
| Brann, WM | 1 |
| Bennett, LE | 1 |
| Keck, BM | 1 |
| Hosenpud, JD | 1 |
| Pascual, J | 1 |
| Crespo, M | 1 |
| Mateos, ML | 1 |
| Marcén, R | 1 |
| Orofino, L | 1 |
| Burgos, FJ | 1 |
| Liaño, F | 1 |
| Ortuño, J | 1 |
| Peddi, VR | 1 |
| Whiting, J | 1 |
| Weiskittel, PD | 1 |
| Alexander, JW | 2 |
| First, MR | 2 |
| Roob, G | 1 |
| Fazekas, F | 1 |
| Hartung, HP | 1 |
| Weinstein, T | 1 |
| Korzets, A | 1 |
| Chagnac, A | 1 |
| Ori, Y | 1 |
| Herman, M | 1 |
| Zevin, D | 1 |
| Malachi, T | 1 |
| Gafter, U | 1 |
| Balducci, L | 1 |
| Extermann, M | 1 |
| Shimada, H | 1 |
| Nakajima, K | 1 |
| Sakamoto, K | 1 |
| Takeda, A | 1 |
| Hori, S | 1 |
| Hayashi, H | 1 |
| Kenmochi, T | 1 |
| Gunji, Y | 1 |
| Suzuki, T | 1 |
| Asano, T | 1 |
| Kashiwabara, H | 1 |
| Yokoyama, K | 1 |
| Arita, S | 1 |
| Ochiai, T | 1 |
| Feinstein, L | 1 |
| Sandmaier, B | 1 |
| Maloney, D | 1 |
| McSweeney, PA | 1 |
| Maris, M | 1 |
| Flowers, C | 1 |
| Radich, J | 1 |
| Little, MT | 1 |
| Nash, RA | 1 |
| Chauncey, T | 1 |
| Woolfrey, A | 1 |
| Georges, G | 1 |
| Kiem, HP | 1 |
| Zaucha, JM | 1 |
| Blume, KG | 1 |
| Shizuru, J | 1 |
| Niederwieser, D | 1 |
| Stratta, P | 1 |
| Canavese, C | 1 |
| Santi, S | 1 |
| Ciccone, G | 1 |
| Rosso, S | 1 |
| Davidson, TG | 1 |
| Bokemeyer, C | 1 |
| Honecker, F | 1 |
| Wedding, U | 1 |
| Späth-Schwalbe, E | 1 |
| Lipp, HP | 1 |
| Kolb, G | 1 |
| Hachulla, E | 1 |
| Ben Taarit, C | 1 |
| Turki, S | 1 |
| Ben Maïz, H | 1 |
| Májský, A | 2 |
| Abrahámová, J | 2 |
| Conte, N | 1 |
| Manente, P | 1 |
| valmachino, G | 1 |
| Gasparini, G | 1 |
| Lo Giudice, C | 1 |
| Fioretti, D | 1 |
| Gasparoni, P | 1 |
| Boneu-Valmalette, A | 1 |
| Bugat, R | 1 |
| David, JF | 1 |
| Combes, PF | 1 |
| Bruntsch, U | 1 |
| Livingston, RB | 1 |
| Sutow, WW | 1 |
| Bingham, CA | 1 |
| Oehninger, C | 1 |
| Rodríguez, T | 1 |
| Passano, R | 1 |
| Casanova, E | 1 |
| Paciel, J | 1 |
| Lasalvia, E | 1 |
| Einhorn, LH | 1 |
| Silver, RT | 1 |
| Young, RC | 3 |
| Holland, JF | 2 |
| Dawkins, RL | 1 |
| Mazzei, D | 1 |
| Polli, EE | 1 |
| Quarto di Palo, F | 1 |
| Sieber, SM | 1 |
| Metheny, JA | 1 |
| Sweet, DL | 1 |
| Ultmann, JE | 1 |
| Santiago Delpin, EA | 1 |
| Green, MR | 1 |
| Kim, HD | 1 |
| Boggs, DR | 1 |
| Woodruff, MF | 1 |
| Nolan, B | 1 |
| Anderton, JL | 1 |
| Abouna, GM | 1 |
| Morton, JB | 1 |
| Jenkins, AM | 1 |
| Puff, KH | 1 |
| Bearden, JD | 1 |
| Coltman, CA | 1 |
| Moon, TE | 1 |
| Costanzi, JJ | 1 |
| Saiki, JH | 1 |
| Balcerzak, SP | 1 |
| Rivkin, SE | 1 |
| Morrison, FS | 1 |
| Lane, M | 1 |
| Spigel, SC | 1 |
| Czaja, AJ | 2 |
| Summerskill, WH | 1 |
| Siering, H | 1 |
| Felsch, G | 1 |
| Barthel, E | 1 |
| Thorpe, P | 1 |
| van Gennip, AH | 1 |
| Tabak-van Gorcum, JA | 1 |
| Taminiau, JA | 1 |
| Wadman, SK | 1 |
| Old, LJ | 1 |
| Krakoff, IH | 1 |
| Bordes-Aznar, J | 1 |
| Mancilla, E | 1 |
| Rosenblum, M | 1 |
| Gabilondo, F | 1 |
| Orozco, R | 1 |
| Angeles, A | 1 |
| Alberú, J | 1 |
| Vilardell, J | 2 |
| Oppenheimer, F | 2 |
| Talbot-Wright, R | 1 |
| Ricart, MJ | 1 |
| Andreu, J | 1 |
| Alcaraz, A | 1 |
| Carretero, P | 1 |
| Shaw, NJ | 1 |
| Elton, R | 1 |
| Eden, OB | 1 |
| Castelao, AM | 1 |
| Puig, JM | 1 |
| Cantarell, MC | 1 |
| Solá, R | 1 |
| Lauzurica, R | 1 |
| Hariharan, S | 1 |
| Schroeder, T | 1 |
| Ryckman, F | 1 |
| Munda, R | 1 |
| Bhat, G | 1 |
| Bolce, R | 1 |
| Dillon, TA | 1 |
| Sullivan, M | 1 |
| Schätzlein, MH | 1 |
| Peterson, AC | 1 |
| Scheeringa, RH | 1 |
| Clark, WR | 1 |
| Ladowski, JS | 1 |
| Velez, RL | 1 |
| Brinker, KR | 1 |
| Vergne-Marini, PJ | 1 |
| Nesser, DA | 1 |
| Long, DL | 1 |
| Trevino, G | 1 |
| Dickerman, RM | 1 |
| Helfrich, GB | 1 |
| Spitzer, G | 1 |
| Hancock, BW | 1 |
| Vaughan Hudson, G | 1 |
| Vaughan Hudson, B | 1 |
| Haybittle, JL | 1 |
| Bennett, MH | 1 |
| MacLennan, KA | 1 |
| Jelliffe, AM | 1 |
| Peters, KM | 1 |
| Pfeiffer, R | 1 |
| Bornhofen, B | 1 |
| Ko, HL | 1 |
| Beuth, J | 1 |
| Grundmann, R | 1 |
| Pulverer, G | 1 |
| Marano, G | 1 |
| Fischioni, P | 1 |
| Graziano, C | 1 |
| Iannone, M | 1 |
| Morisi, G | 1 |
| Coldman, AJ | 1 |
| Goldie, JH | 1 |
| Borden, EC | 2 |
| Hawkins, MJ | 2 |
| Coleman, M | 1 |
| Boyd, DB | 1 |
| Jenkin, D | 1 |
| Doyle, J | 1 |
| Wang, KK | 1 |
| Beaver, SJ | 1 |
| Go, VL | 1 |
| Kuribayashi, T | 1 |
| Kondo, M | 2 |
| Yorozu, A | 1 |
| Hiramatsu, H | 1 |
| Hashimoto, S | 2 |
| Schiller, JH | 1 |
| O'Connell, MJ | 1 |
| Sielaff, K | 1 |
| Anderson, CS | 1 |
| Olweny, CL | 1 |
| Need, AG | 1 |
| Ersbøll, J | 1 |
| Ruderman, MI | 1 |
| Turkewitz, LJ | 1 |
| Harati, Y | 1 |
| Niakan, E | 1 |
| Bénichou, J | 1 |
| Chastang, C | 1 |
| Abdi, EA | 1 |
| Köhler, M | 1 |
| Weigand, W | 1 |
| Chapman, JR | 1 |
| Morris, PJ | 1 |
| Losonczy, H | 1 |
| Nagy, I | 1 |
| Bakchine, H | 1 |
| Brauner, R | 1 |
| Thibaud, E | 1 |
| Rappaport, R | 1 |
| Flamant, F | 1 |
| Griscelli, C | 1 |
| Lemerle, J | 1 |
| Schaison, G | 1 |
| Schweisguth, O | 1 |
| Zucker, JM | 1 |
| Baumgartner, G | 1 |
| Baumgartner, M | 1 |
| Tominaga, S | 1 |
| Ando, Y | 1 |
| Yamashita, S | 1 |
| Uematsu, M | 1 |
| Shigematsu, N | 1 |
| Nishiguchi, I | 1 |
| Klopovich, PM | 1 |
| Trueworthy, RC | 1 |
| Frei, E | 2 |
| Krueger, TC | 1 |
| Tallent, MB | 1 |
| Richie, RE | 1 |
| Johnson, HK | 1 |
| MacDonell, RC | 1 |
| Turner, B | 1 |
| Fries, JF | 1 |
| Bloch, D | 1 |
| Spitz, P | 1 |
| Mitchell, DM | 1 |
| Ahn, YS | 1 |
| Harrington, WJ | 1 |
| Mylvaganam, R | 1 |
| Ayub, J | 1 |
| Pall, LM | 1 |
| Duane, SF | 1 |
| Peterson, BA | 1 |
| Bloomfield, CD | 1 |
| Michels, SD | 1 |
| Hurd, DD | 1 |
| McLaughlin, P | 1 |
| Talpaz, M | 1 |
| Quesada, JR | 1 |
| Saleem, A | 1 |
| Barlogie, B | 1 |
| Gutterman, JU | 2 |
| Bruckner, HW | 1 |
| Flatmark, A | 1 |
| Schell, HW | 1 |
| Gall, DG | 1 |
| Hamilton, JR | 1 |
| Starzl, TE | 1 |
| Groth, CG | 1 |
| Brettschneider, L | 1 |
| Smith, GV | 1 |
| Kashiwagi, N | 1 |
| Thalassinos, NC | 1 |
| Joplin, GF | 1 |
| Frenger, W | 1 |
| Cheikh-Ali, H | 1 |
| Pauly, JL | 1 |
| Han, T | 1 |
| Varkarakis, MJ | 1 |
| Sokal, JE | 1 |
| Sampson, D | 1 |
| Murphy, GP | 1 |
| Christiani, E | 1 |
| Stald, G | 1 |
| Egli, F | 1 |
| Ching, LT | 1 |
| Burgert, EO | 1 |
| Mills, SD | 1 |
| Bergsagel, DE | 1 |
| Jaffe, N | 2 |
| Traggis, D | 1 |
| Das, L | 1 |
| Moloney, WC | 1 |
| Hann, HW | 1 |
| Kim, BS | 1 |
| Nair, R | 1 |
| Singer, Z | 1 |
| Pouillart, P | 1 |
| Schwarzenberg, L | 1 |
| Mathé, G | 2 |
| Schneider, M | 1 |
| Jasmin, C | 1 |
| Hayat, M | 1 |
| Weiner, R | 1 |
| de Vassal, F | 1 |
| Amiel, JL | 1 |
| Beyer, HP | 1 |
| Fajbisowicz, S | 1 |
| Klein, HO | 1 |
| Lawhorn, TI | 1 |
| Stone, HH | 1 |
| Martin, JD | 1 |
| Arseneau, JC | 3 |
| Canellos, GP | 3 |
| Sherins, RJ | 2 |
| Brennan, MJ | 1 |
| Diethelm, AG | 1 |
| Aldrete, JS | 1 |
| Shaw, JF | 1 |
| Cobbs, CG | 1 |
| Hartley, MW | 1 |
| Sterling, WA | 1 |
| Morgan, JM | 1 |
| Guisan, Y | 1 |
| Enderlin, F | 1 |
| Harder, F | 1 |
| Brunner, F | 1 |
| Thiel, G | 1 |
| Bernhardt, JP | 1 |
| Schädeli, J | 1 |
| Mihatsch, M | 1 |
| Mavligit, GM | 1 |
| Reed, RC | 1 |
| Hersh, EM | 2 |
| Nagel, GA | 1 |
| Saccani, F | 1 |
| Becchi, G | 1 |
| Ehrhart, H | 1 |
| Jedrzejczak, W | 1 |
| Siekierzyński, M | 1 |
| van Os, FH | 1 |
| Witte, S | 1 |
| Doll, R | 1 |
| Kinlen, L | 1 |
| Wüstenberg, PW | 1 |
| Goldin, A | 1 |
| Sandberg, JS | 1 |
| Henderson, ES | 1 |
| Newman, JW | 1 |
| Leb, DE | 1 |
| Howell, RS | 1 |
| Isacchi, G | 1 |
| De Rossi, G | 1 |
| Curró, F | 1 |
| Lleander, VC | 1 |
| Goldstein, G | 1 |
| Horsley, JS | 1 |
| Sponzo, RW | 1 |
| Levin, DL | 1 |
| Schnipper, LE | 1 |
| Bonner, H | 1 |
| Johnson, RE | 1 |
| Röthlisberger, C | 1 |
| Donath, A | 1 |
| Poretti, GG | 1 |
| Zuppinger, A | 1 |
| Brun, F | 1 |
| Brunner, KW | 1 |
| Bollag, W | 1 |
| Lieberman, F | 1 |
| Stern, MH | 1 |
| Curtis, AB | 1 |
| Ogston, D | 1 |
| Dawson, AA | 1 |
| Jakoubková, J | 2 |
| Havránková, N | 1 |
| Muggia, FM | 1 |
| Heinemann, HO | 1 |
| Harris, CC | 1 |
| Szreder, W | 1 |
| Kristensen, P | 1 |
| Eridani, S | 1 |
| Esposito, R | 1 |
| Ponti, GB | 1 |
| Giangrande, A | 1 |
| Valentini, R | 1 |
| Carbone, PP | 1 |
| Wong, VG | 1 |
| Freireich, EJ | 1 |
| Kostanecki, W | 1 |
| Kwiatkowska, E | 1 |
| Zborzil, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 1 Study of LY3039478 in Patients With Advanced or Metastatic Cancer[NCT01695005] | Phase 1 | 237 participants (Actual) | Interventional | 2012-10-31 | Completed | ||
| A Phase III Groupwide Study of Dose-Intensive Response-Based Chemotherapy and Radiation Therapy for Children and Adolescents With Newly Diagnosed Intermediate Risk Hodgkin Disease[NCT00025259] | Phase 3 | 1,734 participants (Actual) | Interventional | 2002-09-30 | Completed | ||
| The Benefit/Risk Profile of Pegylated Proline-Interferon Alpha-2b (AOP2014) Added to the Best Available Strategy Based on Phlebotomies in Low-risk Patients With Polycythemia Vera (PV). The Low-PV Randomized Trial[NCT03003325] | Phase 2 | 127 participants (Actual) | Interventional | 2017-02-02 | Completed | ||
| Phase 1/2 Study of Decitabine Alone and/or in Combination With Chemotherapy and/or Cytokine Induced Killer Cell Transfusion in Patients With Relapsed or Refractory Solid Tumors and B Cell Lymphomas[NCT01799083] | Phase 1/Phase 2 | 100 participants (Anticipated) | Interventional | 2012-12-31 | Recruiting | ||
| Addition of Decitabine to Carboplatin-Paclitaxel in First-Line Treatment of Advanced Ovarian Cancer: A Phase 2-3, Open-label, Randomised Controlled Trial[NCT02159820] | Phase 2/Phase 3 | 500 participants (Anticipated) | Interventional | 2014-06-30 | Recruiting | ||
| Rituximab for the Otolaryngologic Manifestations of Granulomatosis With Polyangiitis[NCT02626845] | Phase 4 | 3 participants (Actual) | Interventional | 2015-12-31 | Terminated (stopped due to Slow recruitment) | ||
| Low-dose Glucocorticoids Plus Rituximab Versus High-dose Glucocorticoids Plus Rituximab for Remission Induction in ANCA-associated Vasculitis; a Multicentre, Open Label, Randomised Control Trial[NCT02198248] | Phase 4 | 140 participants (Actual) | Interventional | 2014-10-31 | Active, not recruiting | ||
| Biosimilars of Rituximab in ANCA-associated Vasculitis Compared to the Originator (BRAVO): a CanVasc Multicentre Study[NCT05716334] | 240 participants (Anticipated) | Observational | 2021-06-15 | Recruiting | |||
| Salvage Therapy for Patients With Inadequate Response to Standard of Care Therapy in Granulomatosis With Polyangiitis[NCT04871191] | Phase 2 | 42 participants (Anticipated) | Interventional | 2023-03-31 | Not yet recruiting | ||
| Rituximab Therapy for the Induction of Remission and Tolerance in ANCA-Associated Vasculitis (ITN021AI)[NCT00104299] | Phase 2/Phase 3 | 197 participants (Actual) | Interventional | 2005-01-31 | Completed | ||
| Rituximab for Anti-neutrophil Cytoplasmic Antibodies (ANCA)-Associated Vasculitis (RAVE) Long-Term Follow-Up Study[NCT01586858] | 67 participants (Actual) | Observational | 2012-05-31 | Terminated (stopped due to Loss of Funding) | |||
| Maintenance of ANCA Vasculitis Remission by Intermittent Rituximab Dosing Based on B-cell Reconstitution vs a Serologic ANCA Flare[NCT02749292] | Phase 4 | 115 participants (Actual) | Interventional | 2016-06-30 | Terminated (stopped due to Due to the coronavirus disease 2019 (COVID-19) pandemic and the deleterious impact of rituximab on vaccination efficacy, the trial was concluded before reaching the target enrollment of 200.) | ||
| Efficacy and Safety of Rituximab in the Treatment of Good Prognosis Microscopic Polyangiitis[NCT03920722] | Phase 3 | 8 participants (Actual) | Interventional | 2020-10-24 | Active, not recruiting | ||
| An International, Open Label, Randomised Controlled Trial Comparing Rituximab With Azathioprine as Maintenance Therapy in Relapsing ANCA-associated Vasculitis[NCT01697267] | Phase 3 | 188 participants (Actual) | Interventional | 2013-04-30 | Completed | ||
| A Randomized Study of a New Medical Device for Oral Mucositis (MDOM Trial)[NCT05104268] | Phase 1/Phase 2 | 100 participants (Anticipated) | Interventional | 2021-11-30 | Not yet recruiting | ||
| A Phase 1/Phase 2 Study for the Prevention of Oral Mucositis (SPOM)[NCT05338398] | Phase 1/Phase 2 | 100 participants (Anticipated) | Interventional | 2022-04-15 | Enrolling by invitation | ||
| Phase I Study of Multiple Ascending Dose, to Investigate the Safety and Tolerability of the Use of Copaiba in Patients With Oral Cancer Submitted to Radiotherapy[NCT05308732] | Phase 1 | 36 participants (Anticipated) | Interventional | 2021-05-11 | Recruiting | ||
| A Randomized Trial of Tamoxifen Combined With Amphotericin B and Fluconazole for Cryptococcal Meningitis[NCT03112031] | Phase 2 | 50 participants (Actual) | Interventional | 2017-10-10 | Completed | ||
| Elderly Cancer PatIents Treated for Advanced or Metastatic Melanoma or NSCLC, Safety and qualiTy of Life Under immunOtheraPies: a Phase IV Trial[NCT03673332] | Phase 4 | 300 participants (Anticipated) | Interventional | 2019-08-09 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of participants with complete response and very good partial response at the end of protocol therapy. (NCT00025259)
Timeframe: Protocol therapy: the overall duration of which is: (n=1527) an average of 137.1 days, median 133.0 days, interquartile range: 101.0, 164.0 days.
| Intervention | Number of participants (Number) |
|---|---|
| Arm I (Patients Off-therapy Before Callback-Induction Only) | 5 |
| Arm II (RER With CR [ABVE-PC, IFRT]) | 370 |
| Arm III (RER With CR [ABVE-PC]) | 380 |
| Arm IV (RER With Less Than CR [ABVE-PC, IFRT]) | 538 |
| Arm V (RER With PD) | 29 |
| Arm VI (SER [DECA, ABVE-PC, IFRT]) | 105 |
| Arm VII (SER [ABVE-PC, IFRT]) | 100 |
Probability of event-Free survival which is defined as the time from study entry to treatment failure (disease progression, disease recurrence, biopsy positive residual after completion of all protocol therapy), occurrence of a second malignant neoplasm, or death from any cause. Patients without report of such events where censored at last contact. (NCT00025259)
Timeframe: 5 years
| Intervention | Probability of survival (Number) |
|---|---|
| Arm I (Patients Off-therapy Before Callback-Induction Only) | 0.89 |
| Arm II (RER With CR [ABVE-PC, IFRT]) | 0.87 |
| Arm III (RER With CR [ABVE-PC]) | 0.84 |
| Arm IV (RER With Less Than CR [ABVE-PC, IFRT]) | 0.87 |
| Arm V (RER With PD) | 0.70 |
| Arm VI (SER [DECA, ABVE-PC, IFRT]) | 0.79 |
| Arm VII (SER [ABVE-PC, IFRT]) | 0.74 |
Occurrence of any grade 4 non-hematologic toxicity or grade 3 non-hematologic toxicity which doesn't respond to treatment within 7 days despite recommended therapy modification, or toxic death, which is any death primarily attributable to treatment. Grade 3 is defined to be severe or medically significant but not immediate life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care ADL. Grade 4 refers to toxicities with life-threatening consequences; urgent intervention indicated. (NCT00025259)
Timeframe: Protocol therapy: the overall duration of which is: (n=1684) an average of 137.3 days, median 133.0 days, interquartile range: 101.0, 164.0 days.
| Intervention | Number of participants (Number) |
|---|---|
| Arm I (Patients Off-therapy Before Callback-Induction Only) | 10 |
| Arm II (RER With CR [ABVE-PC, IFRT]) | 153 |
| Arm III (RER With CR [ABVE-PC]) | 130 |
| Arm IV (RER With Less Than CR [ABVE-PC, IFRT]) | 216 |
| Arm V (RER With PD) | 11 |
| Arm VI (SER [DECA, ABVE-PC, IFRT]) | 62 |
| Arm VII (SER [ABVE-PC, IFRT]) | 45 |
Probability of overall survival which is defined as the time from study entry to death from any cause. Patients alive where censored at last contact. (NCT00025259)
Timeframe: 5 years
| Intervention | Probability of survival (Number) |
|---|---|
| Arm I (Patients Off-therapy Before Callback-Induction Only) | 0.93 |
| Arm II (RER With CR [ABVE-PC, IFRT]) | 0.98 |
| Arm III (RER With CR [ABVE-PC]) | 0.98 |
| Arm IV (RER With Less Than CR [ABVE-PC, IFRT]) | 0.98 |
| Arm VI (SER [DECA, ABVE-PC, IFRT]) | 0.96 |
| Arm VII (SER [ABVE-PC, IFRT]) | 0.93 |
A Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) score of 0 with prednisone taper successfully completed at six months. The BVAS/WG is a validated disease activity index. The BVAS/WG is designed to document new or worsening clinically active vasculitis and consists of a set of items divided into nine organ based systems. BVAS/WG scores range from 0 to 63, with higher scores indicating more active disease. (NCT00104299)
Timeframe: 6 months post-randomization
| Intervention | Participants (Number) |
|---|---|
| Rituximab | 63 |
| Control Group | 52 |
"The 2-sided 95% CI of the percentage of participants who have a Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG)[1] of 0 and have successfully completed the glucocorticoid taper by 6 months post-randomization and the 2-sided 95% CI of the difference between two arms for assessing the superiority of rituximab to control~[1] The BVAS/WG is a disease activity index designed to document new or worsening clinically active vasculitis consisting of items divided into 9 organ based systems. BVAS/WG scores range from 0 to 63, with higher scores indicating more active disease" (NCT00104299)
Timeframe: 6 months post-randomization
| Intervention | participants (Number) |
|---|---|
| Rituximab | 62 |
| Control Group | 51 |
Number of subjects according to originally received treatment that experienced a serious adverse event through 18 months post-randomization or prior to being censored from analyses due to crossover, switching to open-label treatment, or best medical judgment for censor. Events are categorized by coded system organ classes (SOC). Within each SOC, a participant was counted once if the participant reported one or more events coded to that SOC. (NCT00104299)
Timeframe: Randomization to censor at Crossover, Open-label or Best Medical Judgment (up to 18 months post-randomization)
| Intervention | participants (Number) | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Participants with at least one SAE | Blood and Lymphatic System Disorders | Cardiac Disorders | Eye Disorders | Gastrointestinal Disorders | General Disorders and Administration Site | Immune System Disorders | Infections and Infestations | Injury, Poisoning, and Procedural Complications | Investigations | Metabolism and Nutrition Disorders | Musculoskeletal and Connective Tissue Disorders | Neoplasms Benign, Malignant, and Unspecified | Nervous System Disorders | Pregnancy, Puerperium, and Perinatal Conditions | Psychiatric Disorders | Renal and Urinary Disorders | Respiratory, Thoracic, and Mediastinal Disorders | Vascular Disorders | |
| Control Group | 37 | 5 | 2 | 1 | 1 | 3 | 2 | 12 | 0 | 0 | 2 | 3 | 2 | 0 | 0 | 1 | 3 | 8 | 7 |
| Rituximab | 42 | 4 | 2 | 1 | 4 | 5 | 2 | 12 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 4 | 8 | 1 |
The adverse event rate for the following events considered related to vasculitis: Death; Grade 2 or higher leukopenia or thrombocytopenia; Grade 3 or higher infections; Hemorrhagic cystitis (grade 2 or lower needs confirmation by cytoscopy); Malignancy; Venous thromboembolic event (deep venous thrombosis or pulmonary embolism); Hospitalization resulting either from the disease or from a complication due to study treatment; Infusion reactions (within 24 hours of infusion) that result in the cessation of further infusions (including cytokine release allergic reaction); Cerebrovascular accident (NCT00104299)
Timeframe: Through common close-out (defined as 18 months after the last participant is enrolled in the trial)
| Intervention | participants (Number) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Death | Grade 2 or Higher Leukopenia | Grade 2 or Higher Thrombocytopenia | Grade 3 or Higher Infections | Hemorrhagic Cystitis (Grade 2 or Lower) | Malignancy | Venous Thromboembolic Event | Hospitalization Resulting from the Disease | Cerebrovascular Accident (CVA) | Infusion Reactions Leading to Infusion Disc. | |
| Control Group | 2 | 23 | 1 | 16 | 1 | 2 | 8 | 7 | 1 | 0 |
| Rituximab | 2 | 7 | 4 | 18 | 2 | 5 | 6 | 16 | 1 | 1 |
"Duration of complete remission is defined as a Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG)[1] of 0 and a completing taper of Prednisone to the first flare, BVAS/WG score of greater than 0, or an increase in Prednisone dosing.~[1] The BVAS/WG is a disease activity index designed to document new or worsening clinically active vasculitis consisting of items divided into 9 organ based systems. BVAS/WG scores range from 0 to 63, with higher scores indicating more active disease" (NCT00104299)
Timeframe: 18 months post-randomization
| Intervention | Days (Number) | ||
|---|---|---|---|
| 25% Quartile (95%CI) | 50% Quartile (95%CI) | 75% Quartile (95%CI) | |
| Control Group | 230 | NA | NA |
| Rituximab | 243 | NA | NA |
Duration of remission is defined as a Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG)[1] of 0 and a completing taper of glucocorticoid by 6 months post-randomization to the first flare, BVAS/WG score of greater than 0, or an increase in Prednisone dosing. (NCT00104299)
Timeframe: 18 months post-randomization
| Intervention | Days (Number) | ||
|---|---|---|---|
| 25% Quartile (95%CI) | 50% Quartile (95%CI) | 75% Quartile (95%CI) | |
| Control Group | 168 | NA | NA |
| Rituximab | 246 | NA | NA |
"Time to complete remission is defined as the number of days from baseline visit (Visit 1) to a Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG)[1] of 0 and completing taper of glucocorticoid by 6 months post-randomization.~[1] The BVAS/WG is a disease activity index designed to document new or worsening clinically active vasculitis consisting of items divided into 9 organ based systems. BVAS/WG scores range from 0 to 63, with higher scores indicating more active disease" (NCT00104299)
Timeframe: 18 months post-randomization
| Intervention | Days (Number) | ||
|---|---|---|---|
| 25% Quartile (95%CI) | 50% Quartile (95%CI) | 75% Quartile (95%CI) | |
| Control Group | 177 | 183 | 266 |
| Rituximab | 176 | 180 | 189 |
"Time to complete remission is defined as the number of days from baseline visit (Visit 1) to a Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG)[1] of 0.~[1] The BVAS/WG is a disease activity index designed to document new or worsening clinically active vasculitis consisting of items divided into 9 organ based systems. BVAS/WG scores range from 0 to 63, with higher scores indicating more active disease" (NCT00104299)
Timeframe: 18 months post-randomization
| Intervention | Days (Number) | ||
|---|---|---|---|
| 25% Quartile (95%CI) | 50% Quartile (95%CI) | 75% Quartile (95%CI) | |
| Control Group | 29 | 43 | 112 |
| Rituximab | 30 | 57 | 119 |
Number of disease relapse added with the number of SAE in each group (NCT02749292)
Timeframe: Median follow-up period of 4.1 years (IQR, 2.5 - 5.0)
| Intervention | Number of events (Number) |
|---|---|
| B Cell Reconstitution | 27 |
| Serologic ANCA Flare | 36 |
The rituximab utilization was measured in how many times a subject received Rituximab throughout the study which was then averaged for all subjects in each treatment arm, including those who did not receive any infusion. (NCT02749292)
Timeframe: Median follow-up period of 4.1 years (IQR, 2.5 - 5.0)
| Intervention | Infusions per subject (Mean) |
|---|---|
| B Cell Reconstitution | 3.6 |
| Serologic ANCA Flare | 0.5 |
The Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG ) is a form with 34 predefined items grouped into 9 organ systems. The items are clinical features observed in patients with active ANCA vasculitis. Each item has a specified weight of either 3 or 1, depending on whether it reflects major or minor disease activity. The total BVAS/WG score is the weighted sum of individual manifestations that are present and believed to be due to active ANCA vasculitis. Higher scores reflect more active disease. BVAS/WG scores range from 0 to 64. (NCT02749292)
Timeframe: Median follow-up period of 4.1 years (IQR, 2.5 - 5.0)
| Intervention | number of events (Number) |
|---|---|
| B Cell Reconstitution | 4 |
| Serologic ANCA Flare | 7 |
Number of patients with serious adverse events (SAEs), including all episodes of late onset neutropenia (LON). SAE are defined in the Serious adverse event section. Serious adverse events were reported over the entire study period (5.5 years) (NCT02749292)
Timeframe: Median follow-up period of 4.1 years (IQR, 2.5 - 5.0)
| Intervention | Participants (Count of Participants) |
|---|---|
| B Cell Reconstitution | 15 |
| Serologic ANCA Flare | 14 |
Hypogammaglobulinemia defined as an IgG < 250mg/dL (NCT02749292)
Timeframe: Median follow-up period of 4.1 years (IQR, 2.5 - 5.0)
| Intervention | Participants (Count of Participants) |
|---|---|
| B Cell Reconstitution | 1 |
| Serologic ANCA Flare | 0 |
number of deaths throughout the study. (NCT02749292)
Timeframe: 5.5 years
| Intervention | number of deaths (Number) |
|---|---|
| B Cell Reconstitution | 2 |
| Serologic ANCA Flare | 0 |
The Short Form (36) Health Survey is a 36-item, patient-reported survey of patient health. The SF-36 is a measure of health status and is commonly used in health economics as a variable in the quality-adjusted life year calculation to determine the cost-effectiveness of a health treatment. The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability. (NCT02749292)
Timeframe: Assessed throughout the study period, every 6 months unless such time point was not reached or was missed by the patient. Median follow-up period is of 4.1 years (IQR, 2.5 - 5.0)
| Intervention | score on a scale (Mean) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Physical functioning at 6 months | Role functioning/physical at 6 months | Role functioning/emotional at 6 months | Energy/fatigue at 6 months | Emotional well-being at 6 months | Social functioning at 6 months | Pain at 6 months | General health at 6 months | Physical functioning at 36 months | Role functioning/physical at 36 months | Role functioning/emotional at 36 months | Energy/fatigue at 36 months | Emotional well-being at 36 months | Social functioning at 36 months | Pain at 36 months | General health at 36 months | Physical functioning at 12 months | Role functioning/physical at 12 months | Role functioning/emotional at 12 months | Energy/ fatigue at 12 months | Emotional well-being at 12 months | Social functioning at 12 months | Pain at 12 months | General health at 12 months | Physical functioning at 18 months | Role functioning/physical at 18 months | Role functioning/emotional at 18 months | Energy/fatigue at 18 months | Emotional well-being at 18 months | Social functioning at 18 months | Pain at 18 months | General health at 18 months | Physical functioning at 24 months | Role functioning/physical at 24 months | Role functioning/emotional at 24 months | Energy/fatigue at 24 months | Emotional well-being at 24 months | Social functioning at 24 months | Pain at 24 months | General health at 24 months | Physical functioning at 30 months | Role functioning/physical at 30 months | Role functioning/emotional at 30 months | Energy/fatigue at 30 months | Emotional well-being at 30 months | Social functioning at 30 months | Pain at 30 months | General health at 30 months | Physical functioning at 42 months | Role functioning/physical at 42 months | Role functioning/emotional at 42 months | Energy/fatigue at 42 months | Emotional well-being at 42 months | Social functioning at 42 months | Pain at 42 months | General health at 42 months | Physical functioning at 48 months | Role functioning/physical at 48 months | Role functioning/emotional at 48 months | Energy/fatigue at 48 months | Emotional well-being at 48 months | Social functioning at 48 months | Pain at 48 months | General health at 48 months | Physical functioning at 60 months | Role functioning/physical at 60 months | Role functioning/emotional at 60 months | Energy/fatigue at 60 months | Emotional well-being at 60 months | Social functioning at 60 months | Pain at 60 months | General health at 60 months | |
| Serologic ANCA Flare | 82 | 65 | 75 | 67 | 81 | 88 | 82 | 63 | 88 | 79 | 82 | 73 | 84 | 95 | 87 | 70 | 82 | 63 | 68 | 65 | 81 | 86 | 80 | 63 | 82 | 62 | 74 | 68 | 81 | 92 | 82 | 67 | 88 | 71 | 80 | 76 | 85 | 94 | 82 | 70 | 88 | 72 | 80 | 72 | 84 | 94 | 83 | 70 | 82 | 60 | 76 | 70 | 85 | 87 | 82 | 63 | 95 | 100 | 100 | 75 | 85 | 100 | 80 | 75 | 92 | 100 | 89 | 71 | 83 | 92 | 83 | 70 |
The Short Form (36) Health Survey is a 36-item, patient-reported survey of patient health. The SF-36 is a measure of health status and is commonly used in health economics as a variable in the quality-adjusted life year calculation to determine the cost-effectiveness of a health treatment. The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale. The lower the score the more disability. The higher the score the less disability i.e., a score of zero is equivalent to maximum disability and a score of 100 is equivalent to no disability. (NCT02749292)
Timeframe: Assessed throughout the study period, every 6 months unless such time point was not reached or was missed by the patient. Median follow-up period is of 4.1 years (IQR, 2.5 - 5.0)
| Intervention | score on a scale (Mean) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Physical functioning at 6 months | Role functioning/physical at 6 months | Role functioning/emotional at 6 months | Energy/fatigue at 6 months | Emotional well-being at 6 months | Social functioning at 6 months | Pain at 6 months | General health at 6 months | Physical functioning at 36 months | Role functioning/physical at 36 months | Role functioning/emotional at 36 months | Energy/fatigue at 36 months | Emotional well-being at 36 months | Social functioning at 36 months | Pain at 36 months | General health at 36 months | Physical functioning at 12 months | Role functioning/physical at 12 months | Role functioning/emotional at 12 months | Energy/ fatigue at 12 months | Emotional well-being at 12 months | Social functioning at 12 months | Pain at 12 months | General health at 12 months | Physical functioning at 18 months | Role functioning/physical at 18 months | Role functioning/emotional at 18 months | Energy/fatigue at 18 months | Emotional well-being at 18 months | Social functioning at 18 months | Pain at 18 months | General health at 18 months | Physical functioning at 24 months | Role functioning/physical at 24 months | Role functioning/emotional at 24 months | Energy/fatigue at 24 months | Emotional well-being at 24 months | Social functioning at 24 months | Pain at 24 months | General health at 24 months | Physical functioning at 30 months | Role functioning/physical at 30 months | Role functioning/emotional at 30 months | Energy/fatigue at 30 months | Emotional well-being at 30 months | Social functioning at 30 months | Pain at 30 months | General health at 30 months | Physical functioning at 42 months | Role functioning/physical at 42 months | Role functioning/emotional at 42 months | Energy/fatigue at 42 months | Emotional well-being at 42 months | Social functioning at 42 months | Pain at 42 months | General health at 42 months | Physical functioning at 48 months | Role functioning/physical at 48 months | Role functioning/emotional at 48 months | Energy/fatigue at 48 months | Emotional well-being at 48 months | Social functioning at 48 months | Pain at 48 months | General health at 48 months | Physical functioning at 54 months | Role functioning/physical at 54 months | Role functioning/emotional at 54 months | Energy/fatigue at 54 months | Emotional well-being at 54 months | Social functioning at 54 months | Pain at 54 months | General health at 54 months | Physical functioning at 60 months | Role functioning/physical at 60 months | Role functioning/emotional at 60 months | Energy/fatigue at 60 months | Emotional well-being at 60 months | Social functioning at 60 months | Pain at 60 months | General health at 60 months | |
| B Cell Reconstitution | 84 | 66 | 79 | 65 | 83 | 89 | 79 | 66 | 74 | 50 | 65 | 58 | 76 | 83 | 69 | 60 | 79 | 61 | 82 | 65 | 86 | 92 | 81 | 66 | 83 | 70 | 88 | 69 | 85 | 96 | 84 | 68 | 83 | 71 | 84 | 68 | 82 | 91 | 81 | 69 | 85 | 74 | 87 | 64 | 81 | 90 | 86 | 60 | 76 | 58 | 67 | 60 | 77 | 85 | 83 | 59 | 65 | 67 | 67 | 52 | 73 | 65 | 70 | 61 | 88 | 50 | 67 | 67 | 84 | 84 | 81 | 59 | 72 | 33 | 100 | 48 | 82 | 63 | 53 | 58 |
Number of infections mild and severe, whether they were treated or not with antibiotics (NCT02749292)
Timeframe: Median follow-up period of 4.1 years (IQR, 2.5 - 5.0)
| Intervention | number of events (Number) | |
|---|---|---|
| Serious Adverse Events- Infections | Adverse Events- Infections | |
| B Cell Reconstitution | 12 | 72 |
| Serologic ANCA Flare | 6 | 59 |
Relapses recording period was from 6/1/2016 to 12/31/2021. The outcome was reported as the number of participants with disease relapse who had either positive ANCA titers specific for myeloperoxidase (MPO-ANCA) or proteinase 3 (PR3-ANCA). The Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG ) is a form with 34 predefined items grouped into 9 organ systems. The items are clinical features observed in patients with active ANCA vasculitis. Each item has a specified weight of either 3 or 1, depending on whether it reflects major or minor disease activity. The total BVAS/WG score is the weighted sum of individual manifestations that are present and believed to be due to active ANCA vasculitis. Higher scores reflect more active disease. BVAS/WG scores range from 0 to 64. (NCT02749292)
Timeframe: Median follow-up period of 4.1 years (IQR, 2.5 - 5.0)
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| PR3 | MPO | |
| B Cell Reconstitution | 1 | 4 |
| Serologic ANCA Flare | 7 | 7 |
The Vasculitis Damage Index (VDI) is a validated formal assessment tool in ANCA-associated vasculitis clinical trials. The VDI distinguishes vasculitis-induced chronic damage from active inflammation or persistent disease. Each item represents a disease manifestation and is given a score (of 1) if present for at least 3 months. Neither the cause of damage (vasculitis vs treatment) nor an ongoing activity are taken into consideration. The VDI includes 64 items categorized into 11 groups (by organ system) and the scored items are summed to give a total score ranging from 0 to 64. A higher score means more accrued damage. (NCT02749292)
Timeframe: 3 years starting at inclusion
| Intervention | score on a scale (Mean) | |
|---|---|---|
| VDI at inclusion | VDI at 3 years | |
| B Cell Reconstitution | 1.27 | 1.42 |
| Serologic ANCA Flare | 1.07 | 1.08 |
The 36-Item Short Form Health Survey (SF-36) is a set of generic, coherent, and easily administered quality-of-life measures. Scores for the scale range from 0-100 and transformed to have a mean of 50 and SD of 10 in the reference population, with higher scores indicating a better Health-related Quality of Life. (NCT01697267)
Timeframe: 12 months
| Intervention | score on a scale (Mean) |
|---|---|
| Rituximab Maintenance | 50.8 |
| Azathioprine Maintenance | 51.9 |
The 36-Item Short Form Health Survey (SF-36) is a set of generic, coherent, and easily administered quality-of-life measures. Scores for the scale range from 0-100 and transformed to have a mean of 50 and SD of 10 in the reference population, with higher scores indicating a better Health-related Quality of Life. (NCT01697267)
Timeframe: 24 months
| Intervention | score on a scale (Mean) |
|---|---|
| Rituximab Maintenance | 51.9 |
| Azathioprine Maintenance | 53.5 |
The 36-Item Short Form Health Survey (SF-36) is a set of generic, coherent, and easily administered quality-of-life measures. Scores for the scale range from 0-100 and transformed to have a mean of 50 and SD of 10 in the reference population, with higher scores indicating a better Health-related Quality of Life. (NCT01697267)
Timeframe: 36 months
| Intervention | score on a scale (Mean) |
|---|---|
| Rituximab Maintenance | 52.3 |
| Azathioprine Maintenance | 51.8 |
The 36-Item Short Form Health Survey (SF-36) is a set of generic, coherent, and easily administered quality-of-life measures. Scores for the scale range from 0-100 and transformed to have a mean of 50 and SD of 10 in the reference population, with higher scores indicating a better Health-related Quality of Life. (NCT01697267)
Timeframe: 4 months
| Intervention | score on a scale (Mean) |
|---|---|
| Rituximab Maintenance | 51.8 |
| Azathioprine Maintenance | 51.0 |
The 36-Item Short Form Health Survey (SF-36) is a set of generic, coherent, and easily administered quality-of-life measures. Scores for the scale range from 0-100 and transformed to have a mean of 50 and SD of 10 in the reference population, with higher scores indicating a better Health-related Quality of Life. (NCT01697267)
Timeframe: 48 months
| Intervention | score on a scale (Mean) |
|---|---|
| Rituximab Maintenance | 50.9 |
| Azathioprine Maintenance | 53.9 |
The 36-Item Short Form Health Survey (SF-36) is a set of generic, coherent, and easily administered quality-of-life measures. Scores for the scale range from 0-100 and transformed to have a mean of 50 and SD of 10 in the reference population, with higher scores indicating a better Health-related Quality of Life. (NCT01697267)
Timeframe: 12 months
| Intervention | score on a scale (Mean) |
|---|---|
| Rituximab Maintenance | 38.2 |
| Azathioprine Maintenance | 34.6 |
The 36-Item Short Form Health Survey (SF-36) is a set of generic, coherent, and easily administered quality-of-life measures. Scores for the scale range from 0-100 and transformed to have a mean of 50 and SD of 10 in the reference population, with higher scores indicating a better Health-related Quality of Life. (NCT01697267)
Timeframe: 24 months
| Intervention | score on a scale (Mean) |
|---|---|
| Rituximab Maintenance | 36.7 |
| Azathioprine Maintenance | 35.6 |
The 36-Item Short Form Health Survey (SF-36) is a set of generic, coherent, and easily administered quality-of-life measures. Scores for the scale range from 0-100 and transformed to have a mean of 50 and SD of 10 in the reference population, with higher scores indicating a better Health-related Quality of Life. (NCT01697267)
Timeframe: 36 months
| Intervention | score on a scale (Mean) |
|---|---|
| Rituximab Maintenance | 34.6 |
| Azathioprine Maintenance | 33.8 |
The 36-Item Short Form Health Survey (SF-36) is a set of generic, coherent, and easily administered quality-of-life measures. Scores for the scale range from 0-100 and transformed to have a mean of 50 and SD of 10 in the reference population, with higher scores indicating a better Health-related Quality of Life. (NCT01697267)
Timeframe: 4 months
| Intervention | score on a scale (Mean) |
|---|---|
| Rituximab Maintenance | 36.7 |
| Azathioprine Maintenance | 36.1 |
The 36-Item Short Form Health Survey (SF-36) is a set of generic, coherent, and easily administered quality-of-life measures. Scores for the scale range from 0-100 and transformed to have a mean of 50 and SD of 10 in the reference population, with higher scores indicating a better Health-related Quality of Life. (NCT01697267)
Timeframe: 48 months
| Intervention | score on a scale (Mean) |
|---|---|
| Rituximab Maintenance | 35.8 |
| Azathioprine Maintenance | 35.0 |
Infection (treated with intravenous or oral antibiotics) rates (NCT01697267)
Timeframe: Up to 4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Rituximab Maintenance | 54 |
| Azathioprine Maintenance | 62 |
Severe adverse event (SAE) rate (NCT01697267)
Timeframe: Up to 48 months
| Intervention | Participants (Count of Participants) |
|---|---|
| Rituximab Maintenance | 37 |
| Azathioprine Maintenance | 48 |
Cumulative accrual of damage as measured by the combined damage assessment score (CDA). Each persistent or new occurrence of damage is given a score of 1. The cumulative accrual of damage is obtained by summing across the different types of damage to get an overall score (max score = 64). (NCT01697267)
Timeframe: data in Rows represent the change from randomization (month 4) to months 12, 24, 36, and 48.
| Intervention | score on a scale (Mean) | |||
|---|---|---|---|---|
| Randomisation to month 12 | Randomisation to month 24 | Randomisation to month 36 | Randomisation to month 48 | |
| Azathioprine Maintenance | 0.337 | 0.533 | 0.899 | 1.38 |
| Rituximab Maintenance | 0.275 | 0.571 | 0.676 | 1.09 |
Cumulative glucocorticoid (GC) exposure during the trial. The trial had a common close out date when the final patient reached month 36 in the trial. Patients were followed until month 48 or the common close out date, whichever happened sooner. Therefore, follow up varied between 36 and 48 months. Cumulative glucocorticoid exposure is presented as a dose in mg for during the treatment period (up to month 24) and across the whole trial (until month 48 or common close out when the final patient reached month 36). (NCT01697267)
Timeframe: Up to 48 months
| Intervention | mg (Mean) | |
|---|---|---|
| Overall (randomisation to end of trial) | Maintenance treatment period (randomisation to month 24) | |
| Azathioprine Maintenance | 4780 | 2426 |
| Rituximab Maintenance | 3717 | 2184 |
Proportion of patients who maintain remission at 24 and 48 months (NCT01697267)
Timeframe: 24 and 48 months
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Month 24 | Month 48 | |
| Azathioprine Maintenance | 70 | 44 |
| Rituximab Maintenance | 73 | 54 |
The primary efficacy outcome measure of the trial is relapse-free survival, where a relapse is either major or minor. The primary analysis will be a Cox regression model adjusted for the stratification factors (ANCA type, relapse severity and prednisone induction regimen) for the difference in the distribution of relapse-free survival between the rituximab arm and the azathioprine (control) arm (two-sided at α-level of 5%). (NCT01697267)
Timeframe: Any patients who have not relapsed at up to a maximum of 4 years will be censored.
| Intervention | participants (Number) | ||
|---|---|---|---|
| Total number of patients with a relapse | Total number of patients with a relapse during treatment | Total number of patients with a relapse post treatment | |
| Azathioprine Maintenance | 60 | 32 | 28 |
| Rituximab Maintenance | 38 | 13 | 25 |
41 reviews available for prednisone and Benign Neoplasms
| Article | Year |
|---|---|
Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
Topics: Autoimmunity; Chromosome Mapping; Glucuronides; Glucuronosyltransferase; Humans; Hyperbilirubinemia; | 2000 |
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms; | 2015 |
Topics: Adult; Alcohol Drinking; Ammonia; Animals; Anti-Inflammatory Agents; Area Under Curve; B-Lymphocytes | 2021 |
Topics: Acceptance and Commitment Therapy; Adolescent; Adult; Aged; Aldehydes; Alpinia; Animals; Antibodies, | 2023 |
Prevention and management of co-morbidities in SLE.
Topics: Adrenal Cortex Hormones; Cardiovascular Diseases; Comorbidity; Humans; Lupus Erythematosus, Systemic | 2014 |
[Reversible cortical atrophy secondary to anti-NMDA receptor antibody encephalitis].
Topics: Anti-N-Methyl-D-Aspartate Receptor Encephalitis; Anticonvulsants; Aphasia, Broca; Aspartic Acid; Atr | 2015 |
[Antibody therapy in hematology and oncology - part 1].
Topics: Aged; Alemtuzumab; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, M | 2008 |
[Clinical manifestation of targeted drugs in individualized therapy of malignant tumors].
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2010 |
CANCER GROWTH ENHANCED BY STEROIDS.
Topics: Animals; Carcinogens; Cortisone; Iatrogenic Disease; Neoplasms; Prednisone; Research; Rheumatic Dise | 1963 |
[MEDICAL THERAPY OF MALIGNANT NEOPLASMS].
Topics: Antimetabolites; Antineoplastic Agents; Antiviral Agents; Blood Transfusion; Busulfan; Chlorambucil; | 1964 |
[THERAPY OF HEMOLYMPHOPATHIES WITH PREDNISONE AT HIGH DOSES].
Topics: Hodgkin Disease; Humans; Leukemia; Leukemia, Myeloid; Liver; Lymphoma; Lymphoma, Large B-Cell, Diffu | 1964 |
Presentation of idiopathic retroperitoneal fibrosis in the pediatric population.
Topics: Autoimmune Diseases; Azathioprine; Blood Sedimentation; Child; Combined Modality Therapy; Creatinine | 2003 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms | 2006 |
[Recent developments in chemotherapy of malignant diseases].
Topics: Anthraquinones; Antibodies, Monoclonal; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 1982 |
The price of immunotherapy.
Topics: Antilymphocyte Serum; Autoimmune Diseases; Azathioprine; B-Lymphocytes; Cyclophosphamide; Cyclospori | 1981 |
Hormones in cancer therapy.
Topics: Adrenal Cortex Hormones; Animals; Cats; Dog Diseases; Dogs; Drug Therapy, Combination; Female; Gonad | 1982 |
International Commission for Protection Against Environmental Mutagens and Carcinogens. Cyclosporine A: review of genotoxicity and potential for adverse human reproductive and developmental effects. Report of a Working Group on the genotoxicity of cyclosp
Topics: Animals; Azathioprine; Chromosome Aberrations; Cyclosporine; Fetus; Humans; Neoplasms; Prednisone; R | 1994 |
Peripheral facial palsy: etiology, diagnosis and treatment.
Topics: Acyclovir; Adrenal Cortex Hormones; Anti-Inflammatory Agents; Antiviral Agents; Clinical Trials as T | 1999 |
Nonmyeloablative hematopoietic cell transplantation. Replacing high-dose cytotoxic therapy by the graft-versus-tumor effect.
Topics: Adult; Animals; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Cyclosporine; | 2001 |
Conventional treatment of hypercalcemia of malignancy.
Topics: Calcitonin; Clinical Protocols; Diphosphonates; Drug Costs; Fluid Therapy; Gallium; Humans; Hydrocor | 2001 |
[Adult Still's disease: study of a series of 11 cases].
Topics: Adult; Anemia; Diagnosis, Differential; Exanthema; Female; Ferritins; Fever; Humans; Incidence; Infe | 2002 |
Chemotherapy of solid tumors. Recent advances.
Topics: Adult; Alkylating Agents; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Bronchogenic; Carcinom | 1976 |
The action of antitumor agents: a double-edged sword?
Topics: Alkylating Agents; Animals; Antineoplastic Agents; Azathioprine; Burkitt Lymphoma; Choriocarcinoma; | 1977 |
Dermatomyositis: a vocal and swallowing disease entity.
Topics: Adolescent; Adult; Aged; Animals; Child; Child, Preschool; Deglutition Disorders; Dermatomyositis; D | 1978 |
Chemotherapy of non-Hodgkin lymphoma: the diffuse types.
Topics: Antineoplastic Agents; Central Nervous System Diseases; Cyclophosphamide; Cytarabine; Drug Therapy, | 1978 |
Principles of clinical immunosuppression.
Topics: Antilymphocyte Serum; Azathioprine; Cyclophosphamide; Graft Rejection; Humans; Immunologic Deficienc | 1979 |
[Polymyositis].
Topics: Antineoplastic Agents; Child; Dermatomyositis; Enzymes; Humans; Immunosuppression Therapy; Methotrex | 1976 |
Autotransplantation in solid tumors.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms | 1991 |
Biologic response modifiers as adjuncts to other therapeutic modalities.
Topics: Adjuvants, Immunologic; Animals; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Breast | 1986 |
[Immunosuppressive therapy in kidney transplantation].
Topics: Antilymphocyte Serum; Azathioprine; Dactinomycin; Humans; Immunosuppression Therapy; Kidney Transpla | 1971 |
Chronic diarrhea in childhood: a new look at an old problem.
Topics: Celiac Disease; Chlorides; Chronic Disease; Cystic Fibrosis; Diarrhea; Diet Therapy; Food Hypersensi | 1974 |
An assessment of massive-dose chemotherapy of malignant disease.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Bone Marrow; Bone Marrow Cells; Cell Division; Cyclo | 1971 |
Chemotherapy in solid tumors of childhood.
Topics: Abdominal Neoplasms; Adolescent; Child; Child, Preschool; Cyclophosphamide; Dactinomycin; Eye Neopla | 1972 |
[Immunosuppressive therapy. A survey concerning rationale, risks, indications and contraindications].
Topics: Adolescent; Adult; Azathioprine; Drug Therapy, Combination; Female; Humans; Immune System Diseases; | 1973 |
Recently recognized complications of cancer chemotherapy.
Topics: Antineoplastic Agents; Burkitt Lymphoma; Cyclophosphamide; Death, Sudden; Drug Therapy, Combination; | 1974 |
Corticosteroids in the treatment of solid tumors.
Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Brain Edema; Brain Neoplasms; Breast Neoplasms; Chil | 1973 |
Immunochemotherapy of human cancer.
Topics: Acute Disease; Adjuvants, Immunologic; Adult; Animals; Antineoplastic Agents; BCG Vaccine; Cytarabin | 1974 |
[Plants with cytostatic effect].
Topics: Alkaloids; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Cell Nucleus; Cell Transform | 1970 |
[Chemotherapy of malignant tumors].
Topics: Adenocarcinoma; Adrenal Gland Neoplasms; Alkaloids; Alkylating Agents; Antibiotics, Antineoplastic; | 1968 |
[The hypoglycemia syndrome].
Topics: Alloxan; Angiography; Antibiotics, Antineoplastic; Blood Glucose; Diagnosis, Differential; Diazoxide | 1970 |
The chemotherapy of human and animal acute leukemia.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Asparaginase; Azaserine; Cell Division; | 1971 |
21 trials available for prednisone and Benign Neoplasms
| Article | Year |
|---|---|
A Phase I Study Investigating AZD8186, a Potent and Selective Inhibitor of PI3Kβ/δ, in Patients with Advanced Solid Tumors.
Topics: Abiraterone Acetate; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Chromones; Humans; Lung Neop | 2022 |
Topics: Acceptance and Commitment Therapy; Adolescent; Adult; Aged; Aldehydes; Alpinia; Animals; Antibodies, | 2023 |
Phase 1 study of 2 high dose intensity schedules of the pan-Notch inhibitor crenigacestat (LY3039478) in combination with prednisone in patients with advanced or metastatic cancer.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Area Under Curve; Benzazepines; Biomarkers, Tumor; D | 2021 |
Subsequent malignant neoplasms among children with Hodgkin lymphoma: a report from the Children's Oncology Group.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Child; Cisplatin; Cyclophosph | 2021 |
Use of the Functional Assessment of Cancer Therapy--anemia in persons with myeloproliferative neoplasm-associated myelofibrosis and anemia.
Topics: Anemia; Bayes Theorem; Double-Blind Method; Female; Glucocorticoids; Humans; Male; Myeloproliferativ | 2014 |
Low-dose decitabine-based chemoimmunotherapy for patients with refractory advanced solid tumors: a phase I/II report.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2014 |
Low-dose decitabine-based chemoimmunotherapy for patients with refractory advanced solid tumors: a phase I/II report.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2014 |
Low-dose decitabine-based chemoimmunotherapy for patients with refractory advanced solid tumors: a phase I/II report.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2014 |
Low-dose decitabine-based chemoimmunotherapy for patients with refractory advanced solid tumors: a phase I/II report.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherap | 2014 |
Implementation of a pharmaceutical care programme for patients receiving new molecular-targeted agents in a clinical trial unit.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Dexamethasone; Drug Int | 2018 |
20-year follow-up results of a randomized controlled trial comparing antilymphocyte globulin induction to no induction in renal transplant patients.
Topics: Antilymphocyte Serum; Azathioprine; Combined Modality Therapy; Cyclosporine; Cytomegalovirus Infecti | 2008 |
A phase I trial of UCN-01 and prednisone in patients with refractory solid tumors and lymphomas.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Resistance | 2010 |
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Topics: Administration, Oral; Aged; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal; Antibodi | 2010 |
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Topics: Administration, Oral; Aged; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal; Antibodi | 2010 |
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Topics: Administration, Oral; Aged; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal; Antibodi | 2010 |
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Topics: Administration, Oral; Aged; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal; Antibodi | 2010 |
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Topics: Administration, Oral; Aged; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal; Antibodi | 2010 |
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Topics: Administration, Oral; Aged; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal; Antibodi | 2010 |
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Topics: Administration, Oral; Aged; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal; Antibodi | 2010 |
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Topics: Administration, Oral; Aged; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal; Antibodi | 2010 |
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Topics: Administration, Oral; Aged; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal; Antibodi | 2010 |
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Topics: Administration, Oral; Aged; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal; Antibodi | 2010 |
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Topics: Administration, Oral; Aged; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal; Antibodi | 2010 |
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Topics: Administration, Oral; Aged; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal; Antibodi | 2010 |
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Topics: Administration, Oral; Aged; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal; Antibodi | 2010 |
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Topics: Administration, Oral; Aged; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal; Antibodi | 2010 |
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Topics: Administration, Oral; Aged; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal; Antibodi | 2010 |
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Topics: Administration, Oral; Aged; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal; Antibodi | 2010 |
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Topics: Administration, Oral; Aged; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal; Antibodi | 2010 |
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Topics: Administration, Oral; Aged; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal; Antibodi | 2010 |
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Topics: Administration, Oral; Aged; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal; Antibodi | 2010 |
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Topics: Administration, Oral; Aged; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal; Antibodi | 2010 |
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Topics: Administration, Oral; Aged; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal; Antibodi | 2010 |
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Topics: Administration, Oral; Aged; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal; Antibodi | 2010 |
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Topics: Administration, Oral; Aged; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal; Antibodi | 2010 |
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Topics: Administration, Oral; Aged; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal; Antibodi | 2010 |
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Topics: Administration, Oral; Aged; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal; Antibodi | 2010 |
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Topics: Administration, Oral; Aged; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal; Antibodi | 2010 |
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Topics: Administration, Oral; Aged; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal; Antibodi | 2010 |
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Topics: Administration, Oral; Aged; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal; Antibodi | 2010 |
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Topics: Administration, Oral; Aged; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal; Antibodi | 2010 |
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Topics: Administration, Oral; Aged; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal; Antibodi | 2010 |
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Topics: Administration, Oral; Aged; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal; Antibodi | 2010 |
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Topics: Administration, Oral; Aged; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal; Antibodi | 2010 |
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Topics: Administration, Oral; Aged; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal; Antibodi | 2010 |
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Topics: Administration, Oral; Aged; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal; Antibodi | 2010 |
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Topics: Administration, Oral; Aged; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal; Antibodi | 2010 |
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Topics: Administration, Oral; Aged; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal; Antibodi | 2010 |
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Topics: Administration, Oral; Aged; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal; Antibodi | 2010 |
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Topics: Administration, Oral; Aged; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal; Antibodi | 2010 |
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Topics: Administration, Oral; Aged; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal; Antibodi | 2010 |
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Topics: Administration, Oral; Aged; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal; Antibodi | 2010 |
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Topics: Administration, Oral; Aged; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal; Antibodi | 2010 |
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Topics: Administration, Oral; Aged; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal; Antibodi | 2010 |
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Topics: Administration, Oral; Aged; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal; Antibodi | 2010 |
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Topics: Administration, Oral; Aged; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal; Antibodi | 2010 |
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Topics: Administration, Oral; Aged; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal; Antibodi | 2010 |
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Topics: Administration, Oral; Aged; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal; Antibodi | 2010 |
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Topics: Administration, Oral; Aged; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal; Antibodi | 2010 |
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Topics: Administration, Oral; Aged; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal; Antibodi | 2010 |
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Topics: Administration, Oral; Aged; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal; Antibodi | 2010 |
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Topics: Administration, Oral; Aged; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal; Antibodi | 2010 |
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Topics: Administration, Oral; Aged; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal; Antibodi | 2010 |
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Topics: Administration, Oral; Aged; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal; Antibodi | 2010 |
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Topics: Administration, Oral; Aged; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal; Antibodi | 2010 |
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Topics: Administration, Oral; Aged; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal; Antibodi | 2010 |
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Topics: Administration, Oral; Aged; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal; Antibodi | 2010 |
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Topics: Administration, Oral; Aged; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal; Antibodi | 2010 |
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Topics: Administration, Oral; Aged; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal; Antibodi | 2010 |
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Topics: Administration, Oral; Aged; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal; Antibodi | 2010 |
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Topics: Administration, Oral; Aged; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal; Antibodi | 2010 |
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Topics: Administration, Oral; Aged; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal; Antibodi | 2010 |
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Topics: Administration, Oral; Aged; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal; Antibodi | 2010 |
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Topics: Administration, Oral; Aged; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal; Antibodi | 2010 |
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Topics: Administration, Oral; Aged; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal; Antibodi | 2010 |
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Topics: Administration, Oral; Aged; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal; Antibodi | 2010 |
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Topics: Administration, Oral; Aged; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal; Antibodi | 2010 |
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Topics: Administration, Oral; Aged; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal; Antibodi | 2010 |
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Topics: Administration, Oral; Aged; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal; Antibodi | 2010 |
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Topics: Administration, Oral; Aged; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal; Antibodi | 2010 |
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Topics: Administration, Oral; Aged; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal; Antibodi | 2010 |
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Topics: Administration, Oral; Aged; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal; Antibodi | 2010 |
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Topics: Administration, Oral; Aged; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal; Antibodi | 2010 |
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Topics: Administration, Oral; Aged; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal; Antibodi | 2010 |
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Topics: Administration, Oral; Aged; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal; Antibodi | 2010 |
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Topics: Administration, Oral; Aged; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal; Antibodi | 2010 |
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Topics: Administration, Oral; Aged; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal; Antibodi | 2010 |
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Topics: Administration, Oral; Aged; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal; Antibodi | 2010 |
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Topics: Administration, Oral; Aged; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal; Antibodi | 2010 |
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Topics: Administration, Oral; Aged; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal; Antibodi | 2010 |
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Topics: Administration, Oral; Aged; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal; Antibodi | 2010 |
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Topics: Administration, Oral; Aged; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal; Antibodi | 2010 |
Rituximab versus cyclophosphamide for ANCA-associated vasculitis.
Topics: Administration, Oral; Aged; Antibodies, Antineutrophil Cytoplasmic; Antibodies, Monoclonal; Antibodi | 2010 |
Phase I clinical study of a static magnetic field combined with anti-neoplastic chemotherapy in the treatment of human malignancy: initial safety and toxicity data.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Thera | 2003 |
Oral anticoagulation with warfarin is significantly influenced by steroids and CYP2C9 polymorphisms in children with cancer.
Topics: Adolescent; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Aryl Hydrocarbon Hydroxy | 2008 |
Prognostic influence of tumor-infiltrating mast cells in patients with follicular lymphoma treated with rituximab and CHOP.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined | 2008 |
A phase I trial of high-dose oral tamoxifen and CHOPE.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; | 1995 |
Malignant neoplasms in renal transplant patients: a 24-year experience.
Topics: Azathioprine; Cyclosporine; Drug Therapy, Combination; Female; Humans; Immunosuppression Therapy; Ki | 1992 |
Autotransplantation in solid tumors.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow Transplantation; Breast Neoplasms | 1991 |
British National Lymphoma Investigation randomised study of MOPP (mustine, Oncovin, procarbazine, prednisolone) against LOPP (Leukeran substituted for mustine) in advanced Hodgkin's disease--long term results.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Chlorambucil; Female; Follow-Up S | 1991 |
Biologic response modifiers as adjuncts to other therapeutic modalities.
Topics: Adjuvants, Immunologic; Animals; Antineoplastic Combined Chemotherapy Protocols; BCG Vaccine; Breast | 1986 |
[Prevention of nausea and emesis during cytostatic therapy. Antiemetic efficacy of high-dosage oral metoclopramide without and with prednisone].
Topics: Adult; Aged; Antiemetics; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cis | 1986 |
The chemotherapy of human and animal acute leukemia.
Topics: Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Asparaginase; Azaserine; Cell Division; | 1971 |
[Double-blind study of a corticoid combination as compared with the single components in the hematologic field: preliminary data].
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Antineoplastic Agents; Betamethasone; Clinical Tri | 1970 |
262 other studies available for prednisone and Benign Neoplasms
| Article | Year |
|---|---|
Steriod-associated psychiatric burden in cancer patients.
Topics: Anticonvulsants; Antipsychotic Agents; Humans; Mental Disorders; Neoplasms; Prednisone; Psychotropic | 2023 |
Survival, Nonrelapse Mortality, and Relapse-Related Mortality After Allogeneic Hematopoietic Cell Transplantation: Comparing 2003-2007 Versus 2013-2017 Cohorts.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Female; Hematopoietic Stem Cell Transplantation; H | 2020 |
Cardio-oncology for better lymphoma therapy outcomes.
Topics: Cyclophosphamide; Doxorubicin; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Neoplasms; Prednisone; Ritux | 2020 |
Transient atelectasis due to hilar lymph node swelling affected by lenalidomide-induced tumor flare reaction.
Topics: Antineoplastic Combined Chemotherapy Protocols; Biopsy; Cyclophosphamide; Doxorubicin; Humans; Immun | 2021 |
Mending Broken Hearts: A New Treatment Paradigm for Immune Checkpoint Inhibitor-Induced Myocarditis.
Topics: Abatacept; Evidence-Based Practice; Humans; Immune Checkpoint Inhibitors; Myocarditis; Neoplasms; Pr | 2021 |
Incidence of Infections and Malignancy Among Elderly Male Patients with IBD Exposed to Vedolizumab, Prednisone, and 5-ASA Medications: A Nationwide Retrospective Cohort Study.
Topics: Aged; Antibodies, Monoclonal, Humanized; Cohort Studies; Gastrointestinal Agents; Humans; Incidence; | 2021 |
Making moves: Transitioning R-EPOCH to the ambulatory setting.
Topics: Adult; Aged; Ambulatory Care; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxo | 2018 |
Model-based optimization of G-CSF treatment during cytotoxic chemotherapy.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxo | 2018 |
Optimization of LC method for the quantification of doxorubicin in plasma and urine samples in view of pharmacokinetic, biomedical and drug monitoring therapy studies.
Topics: Adolescent; Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Chromatogra | 2018 |
The Impact of High-Dose Glucocorticoids on the Outcome of Immune-Checkpoint Inhibitor-Related Thyroid Disorders.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents; Antineoplastic Agents, Immunological; Fema | 2019 |
Ipilimumab-induced endocrinopathies: when to start corticosteroids (or not).
Topics: Adrenal Cortex Hormones; Anti-Inflammatory Agents; Antibodies, Monoclonal; Endocrine System Diseases | 2013 |
[ON HODGKIN'S DISEASE. PERSONAL EXPERIENCE].
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Aziridines; Biopsy; Chlorambucil; Classification; Hodg | 1964 |
Rectifying cancer drug discovery through network pharmacology.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biological Products; Cyclopho | 2014 |
Pseudotumours and IgG4-related disease: a case report.
Topics: Aged; Anti-Inflammatory Agents; Biopsy, Fine-Needle; Diagnosis, Differential; Granuloma, Plasma Cell | 2014 |
Predicting response to multidrug regimens in cancer patients using cell line experiments and regularised regression models.
Topics: Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antineoplastic Combined Chemotherapy | 2015 |
Moderating effects of immunosuppressive medications and risk factors for post-operative joint infection following total joint arthroplasty in patients with rheumatoid arthritis or osteoarthritis.
Topics: Aged; Allopurinol; Arthritis, Rheumatoid; Arthroplasty, Replacement; Arthroplasty, Replacement, Hip; | 2017 |
Posterior Reversible Encephalopathy Syndrome Associated With Dose-adjusted EPOCH (Etoposide, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin) Chemotherapy.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Central Nervous System; Cyclophosphamid | 2017 |
[Practical approach to hypereosinophilia].
Topics: Benzamides; Eosinophils; Food Hypersensitivity; Glucocorticoids; Hematologic Diseases; Humans; Hyper | 2008 |
The causes and clinical significance of fever in systemic lupus erythematosus: a retrospective study of 487 hospitalised patients.
Topics: Adult; Anti-Bacterial Agents; Complement C3; Female; Fever; Glucocorticoids; Humans; Lupus Erythemat | 2009 |
[Sweet syndrome in underlying malignancy].
Topics: Aged; Carcinoma, Renal Cell; Disease Progression; Follow-Up Studies; Humans; Kidney Neoplasms; Male; | 2010 |
[Disseminated tuberculosis with splenic abscesses during haemodialysis].
Topics: Abdominal Abscess; Aged; Antitubercular Agents; Biopsy; Diagnosis, Differential; False Negative Reac | 2010 |
[A further possible indication for use of prednisone: several mesenchymal neoplasms].
Topics: Child; Humans; Infant; Leukemia; Leukemia, Myeloid; Liver; Liver Neoplasms; Lymphoma, Large B-Cell, | 1955 |
[Prednisone and mesenchymal neoplasms; case of a primary blastoma of the spleen].
Topics: Humans; Neoplasms; Prednisone; Splenic Neoplasms; Steroids | 1955 |
[Study of the use of prednisone in therapy of malignant hemopathies and neoplasms].
Topics: Hodgkin Disease; Humans; Leukemia; Neoplasms; Prednisone; Steroids | 1955 |
[Use of prednisone with methylandrostenediol in advanced uterine cancer].
Topics: Androgens; Female; Humans; Methandriol; Neoplasms; Prednisone; Uterine Neoplasms | 1956 |
[Use of prednisone with methylandrostenediol in advanced uterine cancer].
Topics: Androgens; Female; Humans; Methandriol; Neoplasms; Prednisone; Uterine Neoplasms | 1956 |
[Use of prednisone with methylandrostenediol in advanced uterine cancer].
Topics: Androgens; Female; Humans; Methandriol; Neoplasms; Prednisone; Uterine Neoplasms | 1956 |
[Use of prednisone with methylandrostenediol in advanced uterine cancer].
Topics: Androgens; Female; Humans; Methandriol; Neoplasms; Prednisone; Uterine Neoplasms | 1956 |
[Dermal sarcoid of forehead in tumoral form; histiomonocytary structure distinct from Besnier-Boeck; remarkable effect of cortancyl].
Topics: Disease; Face; Forehead; Humans; Medical Records; Neoplasms; Prednisone; Sarcoidosis | 1956 |
[Dermal sarcoid of forehead in tumoral form; histiomonocytary structure distinct from Besnier-Boeck; remarkable effect of cortancyl].
Topics: Disease; Face; Forehead; Humans; Medical Records; Neoplasms; Prednisone; Sarcoidosis | 1956 |
[Dermal sarcoid of forehead in tumoral form; histiomonocytary structure distinct from Besnier-Boeck; remarkable effect of cortancyl].
Topics: Disease; Face; Forehead; Humans; Medical Records; Neoplasms; Prednisone; Sarcoidosis | 1956 |
[Dermal sarcoid of forehead in tumoral form; histiomonocytary structure distinct from Besnier-Boeck; remarkable effect of cortancyl].
Topics: Disease; Face; Forehead; Humans; Medical Records; Neoplasms; Prednisone; Sarcoidosis | 1956 |
[Results of combined prednisone (meticorten) and thyroxin therapy in severe cancer of breast].
Topics: Breast; Breast Neoplasms; Humans; Neoplasms; Prednisone; Thyroxine | 1956 |
[Results of combined prednisone (meticorten) and thyroxin therapy in severe cancer of breast].
Topics: Breast; Breast Neoplasms; Humans; Neoplasms; Prednisone; Thyroxine | 1956 |
[Results of combined prednisone (meticorten) and thyroxin therapy in severe cancer of breast].
Topics: Breast; Breast Neoplasms; Humans; Neoplasms; Prednisone; Thyroxine | 1956 |
[Results of combined prednisone (meticorten) and thyroxin therapy in severe cancer of breast].
Topics: Breast; Breast Neoplasms; Humans; Neoplasms; Prednisone; Thyroxine | 1956 |
[Extremely severe acute agranulocytic syndrome treated with deltacortisone: apparent cure; recurrence in 9 months].
Topics: Agranulocytosis; Humans; Neoplasms; Prednisone; Recurrence; Syndrome | 1957 |
[Reticulosarcoma of the scapula; treatment with delta cortisone].
Topics: Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Neoplasms; Prednisone; Sarcoma; Scap | 1957 |
[Carcinomatous meningitis secondary to breast cancer; polioencephalo-myelitic clinical manifestations; transitory and almost complete regression under the action of delta-cortisone; diffuse carcinomatous invasion of the meninges with exclusion of the pare
Topics: Breast Neoplasms; Humans; Meningeal Carcinomatosis; Meningeal Neoplasms; Meninges; Meningitis; Neopl | 1957 |
[Massive dosage of prednisone in lymphogranuloma, lymphosarcoma and reticulum cell sarcoma].
Topics: Hodgkin Disease; Humans; Lymphoma; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Neoplasms | 1957 |
[Evolutive recurrence of serofibrinous pleurisy after discontinuation of cortisone therapy].
Topics: Cortisone; Neoplasms; Pleurisy; Prednisone; Recurrence | 1957 |
[Changes induced in splenic & lymphatic tissue by prolonged cortisone & prednisone therapy in a patient with beta-cell adenoma of the pancreas].
Topics: Cortisone; Humans; Insulinoma; Islands; Islets of Langerhans; Lymph Nodes; Lymphatic Vessels; Lympho | 1958 |
A case of masculinizing ovarian tumor: use of corticosteroid inhibition test in diagnosis.
Topics: 17-Ketosteroids; Adrenal Cortex Hormones; Body Fluids; Female; Humans; Neoplasms; Ovarian Neoplasms; | 1958 |
[Early results of use of prednisone in malignant neoplasms of the female genitalia].
Topics: Female; Genitalia; Genitalia, Female; Humans; Neoplasms; Prednisone; Radiotherapy | 1958 |
Cutaneous lymphoblastoma: a case of reticulum cell sarcoma with prominent skin manifestations and a brief but dramatic remission with prednisone therapy.
Topics: Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Medical Records; Neoplasms; Predniso | 1958 |
Effect of prednisone in the treatment of malignant effusions.
Topics: Humans; Neoplasms; Pleural Effusion, Malignant; Prednisone | 1958 |
[A case of reticulosarcoma treated with large doses of prednisone].
Topics: Cell- and Tissue-Based Therapy; Humans; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Neop | 1959 |
[Prednisone in the treatment of malignant neoplasms].
Topics: Humans; Neoplasms; Prednisone | 1959 |
[Hypoglycemic brain disease caused by probable islet adenoma; disappearance of the disorders under the effect of corticotherapy].
Topics: Adenoma; Brain; Brain Diseases; Hyperinsulinism; Hypoglycemic Agents; Islets of Langerhans; Neoplasm | 1959 |
Desmoid tumor of the abdominal wall: use of prednisone to prevent recurrence in a child.
Topics: Abdominal Neoplasms; Abdominal Wall; Fibroma; Fibromatosis, Aggressive; Medical Records; Neoplasm Re | 1959 |
[On prednisone treatment and the medical aid problem in advanced cancer of the uterus].
Topics: Female; Humans; Neoplasms; Prednisone; Uncompensated Care; Uterine Neoplasms | 1959 |
[Therapeutic experiences with a combination of prednisone and butazolidine].
Topics: Bone and Bones; Bone Neoplasms; Neoplasms; Phenylbutazone; Prednisone; Rheumatic Fever; Thrombophleb | 1959 |
[Gastric cancer with vertebral metastases discovered at the occasion of hematemesis appearing after an inopportune prednisone treatment].
Topics: Bone Neoplasms; Hematemesis; Humans; Medical Records; Neoplasms; Neoplasms, Second Primary; Predniso | 1961 |
Calcium and phosphate metabolism in disseminated breast cancer: effects of site, progression or regression, and hormonal treatment.
Topics: Androgens; Breast; Breast Neoplasms; Calcium; Calcium, Dietary; Humans; Neoplasms; Phosphates; Predn | 1962 |
Multiple myeloma with a large extramedullary plasmacytoma of the thorax treated with prednisone and radiation. metabolic balance study demonstrating unusual beneficial systemic effects of radiation ablation of the plasmacytoma.
Topics: Humans; Multiple Myeloma; Neoplasms; Neoplasms, Plasma Cell; Plasma Cells; Plasmacytoma; Prednisone; | 1962 |
[On the treatment of malignant tumors with tris-ethyleneimonobenzoquinone, 19-norandrostenolone decanoate and prednisone].
Topics: Antineoplastic Agents; Breast Neoplasms; Decanoates; Female; Humans; Nandrolone; Nandrolone Decanoat | 1963 |
[On corticid therapy of malignant tumors].
Topics: Animals; Cortisone; Humans; Neoplasms; Neoplasms, Experimental; Prednisone | 1962 |
[The use of Degranol pills in hemoblastosis and other neoplastic diseases].
Topics: Humans; Leukemia; Leukemia, Lymphoid; Lymphogranuloma Venereum; Lymphoma; Lymphoma, Large B-Cell, Di | 1963 |
[The problem of leukopenia as a side-effect of intravenous long-term therapy of malignant tumors and leukoses with endoxan].
Topics: Blood Transfusion; Cyclophosphamide; Humans; Leukemia; Leukopenia; Neoplasms; Prednisolone; Predniso | 1962 |
[Treatment of advanced breast cancer with corticoids].
Topics: Adrenal Cortex Hormones; Breast; Breast Neoplasms; Humans; Neoplasms; Prednisone | 1962 |
The chemotherapy of intrathoracic tumors.
Topics: Busulfan; Chlorambucil; Cyclophosphamide; Dactinomycin; Humans; Mechlorethamine; Methotrexate; Neopl | 1962 |
Secondary hormonal therapy of disseminated breast cancer. Comparison of hypophysectomy, replacement therapy, estrogens, and androgens.
Topics: Anatomy; Androgens; Antineoplastic Agents; Biological Therapy; Breast Neoplasms; Estrogens; Fluoxyme | 1963 |
[ENZYME DETERMINATIONS IN THE SERUM IN LIVER DISEASES. FUNCTION PATTERNS AS A MEANS OF DIAGNOSIS].
Topics: Alanine Transaminase; Alkaline Phosphatase; Aspartate Aminotransferases; Bilirubin; Cholecystitis; C | 1963 |
THE EFFECT OF CHEMOTHERAPEUTIC AGENTS UPON THE METABOLISM OF INTACT HUMAN CANCER CELLS: AN IN VITRO TECHNIC FOR CELL SENSITIVITY.
Topics: Aminopterin; Antineoplastic Agents; Azaguanine; Carbohydrate Metabolism; In Vitro Techniques; Lactat | 1963 |
CYCLIC HAEMOLYTIC ANAEMIA SYNCHRONOUS WITH PEL-EBSTEIN FEVER IN A CASE OF HODGKIN'S DISEASE.
Topics: Anemia; Anemia, Hemolytic; Antineoplastic Agents; Blood Transfusion; Bronchopneumonia; Fever; Hodgki | 1963 |
PATTERNS OF POLYMYOSITIS AND THEIR RESPONSES TO TREATMENT.
Topics: Adolescent; Alanine Transaminase; Antacids; Aspartate Aminotransferases; Child; Clinical Enzyme Test | 1963 |
THE TREATMENT OF LEUKEMIA.
Topics: Antineoplastic Agents; Busulfan; Chlorambucil; Cyclophosphamide; Leukemia; Mercaptopurine; Methotrex | 1964 |
[HORMONAL THERAPY OF BREAST AND PROSTATIC CARCINOMA].
Topics: Adrenal Cortex Hormones; Adrenalectomy; Androgens; Breast Neoplasms; Castration; Diethylstilbestrol; | 1963 |
CHROMOSOME STUDIES IN LEUKEMIA. I. EVIDENCE FOR THE ORIGIN OF LEUKEMIC STEM LINES FROM ANEUPLOID MUTANTS.
Topics: Aneuploidy; Bone Marrow Examination; Child; Chromosome Aberrations; Chromosome Disorders; Chromosome | 1964 |
[DISSEMINATED MUCORMYCOSIS].
Topics: Antifibrinolytic Agents; Blood Transfusion; Diagnosis; Hodgkin Disease; Mucormycosis; Neoplasms; Pat | 1963 |
A COMPLICATION OF STEROID TREATMENT AFTER RADIOTHERAPY OF CARCINOMA OF THE UTERINE CERVIX; REPORT OF A CASE.
Topics: Carcinoma, Squamous Cell; Cobalt Isotopes; Female; Geriatrics; Humans; Hydrocortisone; Necrosis; Neo | 1964 |
[HOW TO TREAT LEUKEMIA IN 1963].
Topics: Busulfan; Child; Chlorambucil; Humans; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Mercaptopuri | 1963 |
GENERALIZED EXFOLIATIVE ERYTHRODERMA OF TWO YEARS' DURATION.
Topics: Dermatitis, Exfoliative; Diagnosis, Differential; Hodgkin Disease; Humans; Neoplasms; Pathology; Pre | 1964 |
[CAVERN FORMATION IN LUNG METASTASES].
Topics: Caves; Cyclophosphamide; Lung Neoplasms; Neoplasm Metastasis; Neoplasms; Physiology; Prednisone | 1963 |
THE NATURE AND TREATMENT OF DESMOID TUMORS.
Topics: Child; Fibroma; Fibromatosis, Aggressive; Neoplasms; Pathology; Photomicrography; Prednisone; Surgic | 1964 |
HODGKIN'S DISEASE AND HYPOGAMMAGLOBULINAEMIA: A RARE ASSOCIATION.
Topics: Agammaglobulinemia; Anti-Bacterial Agents; Antibiotics, Antitubercular; Chickenpox; Child; Diagnosis | 1964 |
GLOMERULAR FILTRATION IN DISSEMINATED BREAST CANCER.
Topics: Androgens; Breast Neoplasms; Creatine; Creatinine; Estrogens; Humans; Hydrocortisone; Hypophysectomy | 1964 |
SPINAL-CORD COMPRESSION IN THE MALIGNANT LYMPHOMAS.
Topics: Chlorambucil; Hematopoiesis; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Non-Hodgkin; Mercaptopurin | 1964 |
[EXPERIENCE IN THE TREATMENT OF MALIGNANT DISEASES OF THE RETICULOENDOTHELIAL SYSTEM AND LEUKEMIAS. II].
Topics: Betamethasone; Busulfan; Chlorambucil; Copper; Cyclophosphamide; Dexamethasone; Genetic Diseases, X- | 1964 |
[EXPERIENCES IN THE TREATMENT OF MALIGNANT DISEASES OF THE RETICULOENDOTHELIAL SYSTEM AND LEUKEMIAS. (I)].
Topics: Antineoplastic Agents; Cortisone; Hodgkin Disease; Leukemia; Lung Neoplasms; Lymphoma; Lymphoma, Lar | 1964 |
PROPHYLACTIC ENDOCRINE TREATMENT IN CARCINOMA OF THE BREAST.
Topics: Androgens; Breast Neoplasms; Castration; Cortisone; Estrogens; Female; Humans; Mastectomy; Menopause | 1964 |
[KAHLER'S DISEASE TREATED BY THE CORTICOID-CYCLOPHOSPHAMIDE COMBINATION].
Topics: Adrenal Cortex Hormones; Blood Protein Electrophoresis; Cyclophosphamide; Dexamethasone; Humans; Imm | 1964 |
SURGICAL REMOVAL OF TERATOMA OF THE PINEAL REGION.
Topics: Adolescent; Brain Neoplasms; Electrocoagulation; Electroencephalography; Humans; Hydrocortisone; Hyp | 1964 |
ENDOCRINE TREATMENT OF BREAST CANCER.
Topics: Anabolic Agents; Androgens; Breast Neoplasms; Castration; Estrone; Female; Humans; Menopause; Nandro | 1964 |
NONSURGICAL TREATMENT OF PULMONARY CANCER.
Topics: Adenocarcinoma, Bronchiolo-Alveolar; Adrenal Cortex Hormones; Alkylating Agents; Antineoplastic Agen | 1964 |
[THE SIGNIFICANCE OF RETICULOSES IN THE AREA OF MALIGNANT HEMATOLOGICAL DISEASES IN CHILDHOOD].
Topics: Child; Cyclophosphamide; Genetic Diseases, X-Linked; Hematologic Diseases; Histiocytosis, Langerhans | 1963 |
[THE RETICULO-ENDOTHELIAL SYSTEM AND LYMPHOSARCOMAS].
Topics: Adolescent; Adrenal Cortex Hormones; Geriatrics; Hodgkin Disease; Humans; Lymphoma; Lymphoma, Follic | 1964 |
[TREATMENT OF LEUKEMIA].
Topics: Adrenal Cortex Hormones; Antineoplastic Agents; Cyclophosphamide; Humans; Leukemia; Neoplasms; Predn | 1964 |
PLASMA FACTORS IN LEUKAEMIA. IMMUNOLOGICAL AND "IN VITRO" CULTURAL STUDIES.
Topics: Blood Group Antigens; Busulfan; Chlorambucil; Complement Fixation Tests; Coombs Test; Humans; In Vit | 1964 |
[ON ISLET CELL TUMOR].
Topics: Adenoma, Islet Cell; Atropine; Blood Chemical Analysis; Blood Glucose; Epinephrine; Neoplasms; Pancr | 1964 |
[ON ISLET CELL TUMOR].
Topics: Adenoma, Islet Cell; Atropine; Blood Chemical Analysis; Blood Glucose; Epinephrine; Neoplasms; Pancr | 1964 |
[LONG-TERM REMISSIONS OF ACUTE LEUKEMIAS IN CHILDHOOD].
Topics: Adolescent; Child; Humans; Infant; Leukemia; Leukemia, Lymphoid; Leukemia, Myeloid; Mercaptopurine; | 1964 |
ACUTE PROMYELOCYTIC LEUKAEMIA.
Topics: Anemia; Anemia, Myelophthisic; Blood Cell Count; Blood Sedimentation; Bone Marrow Examination; Hemor | 1964 |
HEPATITIS AND--MALIGNANT NEOPLASIA.
Topics: Biopsy; Drug Therapy; Hepatic Encephalopathy; Hepatitis; Hepatitis A; Humans; Hydrocortisone; Hyperb | 1964 |
[DISCUSSIONS ON MAMMARY CANCER. 4. HORMONAL PALLIATIVE TREATMENT].
Topics: Anabolic Agents; Androgens; Breast; Breast Neoplasms; Castration; Estrogens; Female; Humans; Neoplas | 1963 |
DIAGNOSIS AND TREATMENT OF POLYMYOSITIS.
Topics: Adrenal Cortex Hormones; Classification; Clinical Enzyme Tests; Dermatomyositis; Diagnosis; Drug The | 1964 |
[ACUTE MYELOBLASTIC LEUKEMIA WITH PROLONGED COURSE AND ISOLATED AND LATE ENCEPHALO-MENINGEAL LOCALIZATION].
Topics: Bone Marrow Examination; Brain Neoplasms; Cerebrospinal Fluid Proteins; Humans; Leukemia; Leukemia, | 1964 |
HAEMOLYTIC ANAEMIA ASSOCIATED WITH OVARIAN TERATOMA.
Topics: Anemia; Anemia, Hemolytic; Bilirubin; Blood Cell Count; Blood Chemical Analysis; Female; Hemoglobins | 1964 |
[ON THE USE OF A NEW CORTICOID: 16-BETA-METHYL-PREDNISONE].
Topics: Adrenal Cortex Hormones; Geriatrics; Neoplasms; Prednisone; Toxicology | 1964 |
PRIMARY SARCOMA OF THE PERICARDIUM.
Topics: Angiocardiography; Cardiac Surgical Procedures; Drug Therapy; Electrocardiography; Heart Neoplasms; | 1964 |
REGRESSION OF METASTATIC HEPATOMEGALY FROM MAMMARY CARCINOMA. CYTOTOXIC COMBINATION CHEMOTHERAPY WITH 5-FU.
Topics: Breast Neoplasms; Cyclophosphamide; Drug Therapy, Combination; Fluorouracil; Hepatomegaly; Humans; L | 1964 |
RETICULUM CELL SARCOMA OF THE SMALL BOWEL AND STEATORRHOEA.
Topics: Ascorbic Acid; Blood Transfusion; Body Weight; Bone Marrow Examination; Celiac Disease; Diet; Diet T | 1964 |
WATERY DIARRHOEA AND AN ISLET CELL TUMOUR.
Topics: Achlorhydria; Adenoma, Islet Cell; Aldosterone; Cortisone; Dexamethasone; Diarrhea; Feces; Gastrins; | 1964 |
USE OF GAMMA GLOBULIN INFECTION IN ACUTE-LEUKEMIA PATIENTS.
Topics: Abscess; Cellulitis; Colistin; gamma-Globulins; Humans; Infections; Leukemia; Leukemia, Lymphoid; Le | 1964 |
ANDROGENIC HORMONE THERAPY IN LYMPHATIC LEUKEMIA.
Topics: Anemia; Anemia, Aplastic; Erythropoiesis; Fluoxymesterone; Hemoglobins; Humans; Leukemia; Leukemia, | 1964 |
HODGKIN'S DISEASE LIMITED TO THE LIVER.
Topics: Adolescent; Diagnosis, Differential; Hodgkin Disease; Humans; Liver Neoplasms; Neoplasms; Pathology; | 1964 |
NECROTIZING TOXOPLASMIC ENCEPHALITIS AND HERPETIC PNEUMONIA COMPLICATING TREATED HODGKIN'S DISEASE. REPORT OF A CASE.
Topics: Alkylating Agents; Antineoplastic Agents; Cyclophosphamide; Encephalitis; Herpesviridae Infections; | 1965 |
POLYMYOSITIS ASSOCIATED WITH ACUTE MONOCYTIC LEUKEMIA: CASE REPORT AND REVIEW OF THE LITERATURE.
Topics: Biopsy; Bone Marrow Cells; Carcinoma; Humans; Leukemia; Leukemia, Monocytic, Acute; Leukemia, Myeloi | 1964 |
MEDICAL GRAND ROUNDS FROM THE UNIVERSITY OF ALABAMA MEDICAL CENTER.
Topics: Beta-Globulins; Blood Protein Disorders; Bone Marrow Examination; Bone Resorption; Chlorambucil; Dia | 1964 |
[STUDY OF FACTORS INFLUENCING SURVIVAL IN ACUTE LEUKEMIAS].
Topics: Adolescent; Adrenal Cortex Hormones; Child; Drug Therapy; Humans; Leukemia; Leukemia, Lymphoid; Leuk | 1964 |
[DATA TO THE DIAGNOSTIC VALUE OF FIBRINOGEN DETERMINATION IN MALIGNANT DISEASES].
Topics: Cyclophosphamide; Fibrinogen; Hodgkin Disease; Humans; Metaplasia; Myeloproliferative Disorders; Neo | 1964 |
[EXPERIMENTAL ANNOTATIONS ON THE INTRODUCTION OF DRUGS THROUGH THE LYMPHATIC SYSTEM].
Topics: Animals; Humans; Injections; Injections, Intralymphatic; Iodized Oil; Lymph Nodes; Lymphatic System; | 1964 |
CENTRAL NERVOUS SYSTEM INVOLVEMENT BY LEUKEMIA IN CHILDREN. I. RELATIONSHIP TO SYSTEMIC LEUKEMIA AND DESCRIPTION OF CLINICAL AND LABORATORY MANIFESTATIONS.
Topics: Antineoplastic Agents; Central Nervous System Diseases; Child; Clinical Laboratory Techniques; Drug | 1965 |
ASYMPTOMATIC HYPERNATREMIA: PHYSIOLOGICAL AND CLINICAL STUDY.
Topics: Child; Dehydration; Drug Therapy; Humans; Hypernatremia; Hypothalamus; Hypothyroidism; Metabolism; N | 1965 |
THE SUPERIOR MEDIASTINAL SYNDROME IN CHILDREN WITH CANCER.
Topics: Adolescent; Child; Hodgkin Disease; Humans; Leukemia; Lymphoma; Lymphoma, Non-Hodgkin; Mediastinal N | 1965 |
[MODERN TREATMENT OF LEUKEMIA].
Topics: Agranulocytosis; Busulfan; Chlorambucil; Cyclophosphamide; Drug Therapy; Genetic Diseases, X-Linked; | 1965 |
AUTO-IMMUNE HEMOLYTIC ANEMIA TREATED WITH D-PENICILLAMINE; REPORT OF A CASE.
Topics: Anemia; Anemia, Hemolytic; Anemia, Hemolytic, Autoimmune; Autoantibodies; Blood Transfusion; Drug Th | 1965 |
USE OF GLUCOCORTICOIDS IN THE PALLIATIVE TREATMENT OF METASTATIC BRAIN TUMORS.
Topics: Brain Neoplasms; Dexamethasone; Drug Therapy; Geriatrics; Glucocorticoids; Humans; Hydrocortisone; M | 1965 |
HISTIOCYTOSIS X.
Topics: Diagnosis, Differential; Drug Therapy; Genetic Diseases, X-Linked; Histiocytosis, Langerhans-Cell; H | 1965 |
MALIGNANT LYMPHOMA PRESENTING AS NECROTIZING EOSINOPHILIC GRANULOMATOSIS.
Topics: Bone Marrow Examination; Drug Therapy; Eosinophilic Granuloma; Lymphoma; Mechlorethamine; Mercaptopu | 1965 |
MALIGNANT PERICARDIAL EFFUSION. REVIEW OF HOSPITAL EXPERIENCE AND REPORT OF A CASE SUCCESSFULLY TREATED BY TALC POUDRAGE.
Topics: Breast Neoplasms; Cardiac Surgical Procedures; Cardiac Tamponade; Drug Therapy; Exudates and Transud | 1965 |
CADAVERIC RENAL HOMOTRANSPLANTATION WITH INADVERTENT TRANSPLANTATION OF CARCINOMA.
Topics: Antineoplastic Agents; Azathioprine; Carcinoma, Bronchogenic; Drug Therapy; Humans; Immunosuppressiv | 1965 |
HYPERCALCEMIA OF BREAST CANCER; MANAGEMENT WITH CORTICOSTEROIDS.
Topics: Adrenal Cortex Hormones; Breast Neoplasms; Calcium; Carcinoma; Drug Therapy; Geriatrics; Humans; Hyp | 1965 |
FAILURE OF THYMECTOMY TO ALTER THE SUBSEQUENT COURSE OF HUMAN ACUTE LEUKEMIA IN DRUG-INDUCED REMISSION.
Topics: Acute Disease; Adolescent; Aminopterin; Child; Humans; Leukemia; Mercaptopurine; Neoplasms; Predniso | 1965 |
THERAPY OF ACUTE LEUKEMIA, 1965.
Topics: Acute Disease; Adrenal Cortex Hormones; Androgens; Cyclophosphamide; Humans; Leukemia; Mercaptopurin | 1965 |
[RECURRENCE OF DERMATOMYOSITIS FOLLOWING SEVERAL YEARS OF APPARENT RECOVERY].
Topics: Child; Dermatomyositis; Dexamethasone; Drug Therapy; Humans; Neoplasms; Physiological Phenomena; Pre | 1965 |
[WHAT HAS BEEN ACCOMPLISHED BY PREDNISONE THERAPY IN ACUTE LEUKEMIA? (REPORT OF FINDINGS ON 10 YEARS OF PREDNISONE THERAPY)].
Topics: Acute Disease; Child; Humans; Infant; Leukemia; Neoplasms; Prednisone | 1964 |
CLINICAL TRIALS IN PROGRESS: LEUKAEMIA AND MULTIPLE MYELOMA.
Topics: Adolescent; Antineoplastic Agents; Busulfan; Child; Cyclophosphamide; Drug Therapy; Humans; Infant; | 1965 |
Treatment of advanced cancer by tem and by tem combined with irradiation and prednisone.
Topics: Neoplasms; Prednisone; Triethylenemelamine | 1959 |
Perforation of the small bowel in mycosis fungoides treated with prednisone.
Topics: Disease; Humans; Intestinal Diseases; Intestine, Small; Intestines; Mycosis Fungoides; Neoplasms; Pr | 1962 |
Impact of chemotherapy-induced neutropenia on quality of life: a prospective pilot investigation.
Topics: Adaptation, Psychological; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Prot | 2005 |
Immune thrombocytopenia following successful treatment of cancer in children.
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bone Marrow Cells; Carmustine; Child, | 2006 |
99mTc-Annexin A5 uptake and imaging to monitor chemosensitivity.
Topics: Animals; Annexin A5; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosi | 2005 |
Sweet's syndrome presenting as acute hand infection.
Topics: Comorbidity; Dermis; Glucocorticoids; Hand; Humans; Neoplasms; Prednisone; Retrospective Studies; Sk | 2005 |
Gastrointestinal graft-versus-host disease in recipients of autologous hematopoietic stem cells: incidence, risk factors, and outcome.
Topics: Adult; Anti-Inflammatory Agents; Female; Gastrointestinal Diseases; Graft vs Host Disease; Hematopoi | 2006 |
Individualization of immunosuppressive therapy. III. Sirolimus associated with a reduced incidence of malignancy.
Topics: Databases, Factual; Follow-Up Studies; Humans; Immunosuppressive Agents; Incidence; Kidney Transplan | 2006 |
Information sources used by New South Wales cancer clinicians: a qualitative study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubicin; Dru | 2006 |
Salvage chemotherapy for refractory and relapsed posttransplant lymphoproliferative disorders (PTLD) after treatment with single-agent rituximab.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined Chemo | 2007 |
Decrease in peripheral muscle strength and ankle dorsiflexion as long-term side effects of treatment for childhood cancer.
Topics: Ankle; Antineoplastic Agents; Child; Dexamethasone; Female; Humans; Male; Motor Activity; Muscle Str | 2008 |
A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone.
Topics: Adult; Aged; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Combined | 2007 |
Salvage therapy for relapsed posttransplant lymphoproliferative disorders (PTLD) with a second progression of PTLD after Upfront chemotherapy: the role of single-agent rituximab.
Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antineoplastic Agents; Antine | 2007 |
Acute limbic encephalitis: diagnostic and management implications.
Topics: Acute Disease; Antipsychotic Agents; Clonazepam; Confusion; Delirium; Electroencephalography; Humans | 2008 |
My most interesting case.
Topics: Abortion, Induced; Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Doxorubi | 2006 |
[Medical treatment of tumors].
Topics: Antineoplastic Agents; Humans; Neoplasm Metastasis; Neoplasms; Prednisone | 1967 |
Chronic urticaria. Possible causes, suggested treatment alternatives.
Topics: Allergens; Aspirin; Chronic Disease; Drug Administration Schedule; Drug Hypersensitivity; Female; Fo | 1983 |
Evaluation of beta thromboglobulin levels in cancer patients: effects of antitumor chemotherapy.
Topics: Adult; Aged; Beta-Globulins; beta-Thromboglobulin; Cyclophosphamide; Doxorubicin; Drug Therapy, Comb | 1980 |
[Polydermatomyositis in the adult and its management].
Topics: Adrenal Cortex Hormones; Adult; Alcoholism; Dermatomyositis; Female; Humans; Male; Middle Aged; Neop | 1983 |
Lymphoma and leukemia manifested by steroid-responsive polyneuropathy.
Topics: Chronic Disease; Humans; Leukemia, Lymphoid; Lymphatic Diseases; Lymphoma; Male; Middle Aged; Neopla | 1983 |
Effective control of chemotherapy-induced nausea and vomiting with oral prednisone and metoclopramide.
Topics: Administration, Oral; Adult; Cisplatin; Dose-Response Relationship, Drug; Drug Therapy, Combination; | 1984 |
A decision-analysis methodology for consideration of morbidity factors in clinical decision-making.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Decision Making; Hodgkin Disease; Huma | 1984 |
Second malignant neoplasms complicating Hodgkin's disease: the National Cancer Institute experience.
Topics: Adolescent; Adult; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Child; Combine | 1984 |
[Secondary malignant tumors following treatment of Hodgkin's disease].
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophospha | 1984 |
Systemic lupus erythematosus and lymphoma. A family study.
Topics: Adult; Autoimmune Diseases; Azathioprine; Child; Drug Therapy, Combination; Female; Humans; Killer C | 1983 |
Second malignancy complicating Hodgkin's disease.
Topics: Acute Disease; Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cycloph | 1983 |
Thymic rebound after treatment of childhood tumors.
Topics: Child; Child, Preschool; Diagnosis, Differential; Female; Humans; Hypertrophy; Infant; Male; Mediast | 1980 |
[Chagas disease and immunosuppression].
Topics: Adult; Aged; Antineoplastic Agents; Chagas Disease; Chronic Disease; Female; Humans; Immunosuppressi | 1980 |
Sister chromatid exchanges in human lymphocytes treated with combinations of cytotoxic drugs.
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cells, Cultured; Child | 1982 |
A report of five patients with large-volume secretory diarrhea but no evidence of endocrine tumor or laxative abuse.
Topics: Adult; Aged; Cathartics; Chronic Disease; Colon; Diarrhea; Electrolytes; Endocrine System Diseases; | 1982 |
WISC-R verbal/performance discrepancies in pediatric cancer patients.
Topics: Adolescent; Child; Child, Preschool; Female; Humans; Intelligence; Male; Neoplasms; Prednisone; Vinc | 1981 |
Effect of calcitonin and glutocorticoids in combination on the hypercalcemia of malignancy.
Topics: Aged; Calcitonin; Calcium; Drug Therapy, Combination; Female; Humans; Hypercalcemia; Male; Middle Ag | 1980 |
Chemotherapy as a cause of low serum creatine kinase activity.
Topics: Creatine Kinase; Drug Therapy, Combination; Female; Humans; Male; Neoplasms; Prednisone | 1980 |
[Palliative treatment--prednisone for symptoms].
Topics: Brain Neoplasms; Humans; Hypercalcemia; Hypersensitivity; Nausea; Neoplasms; Pain; Palliative Care; | 1994 |
[The significance of preventive CNS irradiation during antineoplastic therapy in childhood with regard to late odontogenic and mandibulofacial injuries].
Topics: Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Cephalometry; Child, Preschool; Combin | 1995 |
Clinical spectrum of clonal proliferations of T-large granular lymphocytes: a T-cell clonopathy of undetermined significance?
Topics: Adult; Aged; Aged, 80 and over; Anemia, Aplastic; Arthritis, Rheumatoid; Blotting, Southern; Bone Ma | 1994 |
De novo malignancy emerges as a major cause of morbidity and late failure in renal transplantation.
Topics: Australia; Azathioprine; Cadaver; Cyclosporine; Female; Humans; Kidney Transplantation; Morbidity; N | 1993 |
Case records of the Department of Medicine University of Mississippi Medical Center. Leukocytoclastic vasculitis, probable polyarteritis nodosa, clinically indolent lymphoma, but never firmly established.
Topics: Aged; Biopsy; Connective Tissue Diseases; Cyclophosphamide; Diagnosis, Differential; Drug Therapy, C | 1997 |
Acute pancreatitis in marrow transplant patients: prevalence at autopsy and risk factor analysis.
Topics: Abdominal Pain; Acute Disease; Adult; Amylases; Bile; Biomarkers; Bone Marrow Transplantation; Cause | 1997 |
Dermatomyositis: a dermatology-based case series.
Topics: Adult; Child; Dermatomyositis; Female; Humans; Male; Middle Aged; Neoplasms; Prednisone; Retrospecti | 1998 |
Morbidity, functional status, and immunosuppressive therapy after heart transplantation: an analysis of the joint International Society for Heart and Lung Transplantation/United Network for Organ Sharing Thoracic Registry.
Topics: Activities of Daily Living; Anti-Inflammatory Agents; Bacterial Infections; Bone Diseases; Cataract; | 1998 |
Reduced severity of acute rejection in hepatitis C virus positive renal allograft recipients: are milder immunosuppressive regimens advisable?
Topics: Cyclosporine; Drug Therapy, Combination; Female; Follow-Up Studies; Graft Rejection; Graft Survival; | 1998 |
Characteristics of long-term renal transplant survivors.
Topics: Adolescent; Adult; Azathioprine; Cadaver; Child; Child, Preschool; Coronary Disease; Female; Follow- | 1998 |
Effect of immunosuppressive therapy on DNA repair and cancer incidence in renal transplant recipients.
Topics: Adult; Aged; Azathioprine; Cyclosporine; DNA Repair; Drug Therapy, Combination; Female; Humans; Immu | 2000 |
Management of cancer in the older person: a practical approach.
Topics: Aged; Aged, 80 and over; Aging; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Do | 2000 |
Existence of serum p53 antibodies in cyclosporine A-treated transplant patients: possible detection of p53 protein over-expression.
Topics: Adolescent; Adult; Aged; Autoantibodies; Biomarkers; Child; Cyclosporine; Female; Gene Expression Re | 2000 |
Systemic lupus erythematosus.
Topics: Antiphospholipid Syndrome; Azathioprine; Cyclophosphamide; Female; Glucocorticoids; Humans; Immunogl | 2001 |
Use of hematopoietic growth factors in elderly patients receiving cytotoxic chemotherapy.
Topics: Aged; Anemia; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamid | 2002 |
[Dermatomyositis and polymyositis: clinical aspects and treatment].
Topics: Anti-Inflammatory Agents; Creatinine; Dermatomyositis; Drug Therapy, Combination; Face; Humans; Immu | 2001 |
Modification of HLA antigens in patients with malignancies following hormone therapy.
Topics: Breast Neoplasms; Diethylstilbestrol; Drug Therapy, Combination; Epitopes; Female; HLA Antigens; Hum | 1978 |
[Therapy of neoplastic hypercalcemia].
Topics: Aged; Calcitonin; Female; Furosemide; Humans; Hypercalcemia; Isotonic Solutions; Male; Middle Aged; | 1978 |
[Kinetics of I-131 fibrinogen in cancer patients: pharmacological approach].
Topics: Aspirin; Blood Coagulation; Fibrinogen; Fibrinolytic Agents; Heparin; Indomethacin; Iodine Radioisot | 1977 |
[Hypercalcemia therapy in malignant tumors].
Topics: Breast Neoplasms; Calcitonin; Female; Fluid Therapy; Humans; Hypercalcemia; Male; Neoplasms; Phospha | 1979 |
Childhood cancer: the improving prognosis.
Topics: Asparaginase; Child; Cyclophosphamide; Cytosine; Daunorubicin; Doxorubicin; Drug Therapy, Combinatio | 1976 |
The cell cycle and cancer chemotherapy.
Topics: Antineoplastic Agents; Cell Cycle; Cyclophosphamide; Cytosine; DNA Replication; Dose-Response Relati | 1978 |
[Immunologic studies in polymyositis syndromes].
Topics: Adult; Aged; Female; Humans; Immunity, Cellular; Immunosuppressive Agents; Male; Middle Aged; Muscle | 1979 |
Cancer chemotherapy.
Topics: Chlorambucil; Choriocarcinoma; Cyclophosphamide; Dactinomycin; Female; Hodgkin Disease; Humans; Leuk | 1977 |
Some new aspects of modern cancer chemotherapy.
Topics: Animals; Antineoplastic Agents; Cell Cycle; Cell Survival; Daunorubicin; Drug Therapy, Combination; | 1977 |
Polymyositis and dermatomyositis: clinical problems.
Topics: Collagen Diseases; Dermatomyositis; Diagnosis, Differential; Humans; Myasthenia Gravis; Myositis; Ne | 1978 |
Malignancy after immunosuppressive therapy.
Topics: Adult; Antilymphocyte Serum; Azathioprine; Dermatomyositis; Female; Humans; Immunosuppression Therap | 1977 |
Pulmonary toxicity in cancer chemotherapy.
Topics: Antineoplastic Agents; Carmustine; Female; Humans; Lung Diseases; Neoplasms; Pneumonia; Prednisone | 1979 |
A syndrome resembling idiopathic thrombocytopenic purpura in 10 patients with diverse forms of cancer.
Topics: Adolescent; Adult; Aged; Female; Humans; Male; Middle Aged; Neoplasms; Prednisone; Purpura, Thromboc | 1979 |
Long survival after renal transplantation in man.
Topics: Adolescent; Adult; Antilymphocyte Serum; Cadaver; Child; Female; Follow-Up Studies; Graft Rejection; | 1976 |
Combination chemotherapy using cyclophosphamide, vincristine, methotrexate, 5-fluorouracil, and prednisone in solid tumors.
Topics: Cyclophosphamide; Drug Therapy, Combination; Female; Fluorouracil; Gastrointestinal Neoplasms; Human | 1977 |
Malignancy in chronic liver disease.
Topics: Adult; Azathioprine; Drug Therapy, Combination; Follow-Up Studies; Humans; Liver Diseases; Middle Ag | 1977 |
[Experiences with cytostatic treatment of malignant tumors].
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Bronchial Neoplasms; Cyclophos | 1976 |
Rheumatoid arthritis treated with chlorambucil: a five-year follow-up.
Topics: Acute Disease; Aged; Arthritis, Rheumatoid; Chlorambucil; Chronic Disease; Female; Follow-Up Studies | 1976 |
The behaviour of LDH-3 in patients with malignant diseases during therapy with cytostatic drugs and prednisone, studied by LDH-isoenzyme electrophoresis on cellulose acetate.
Topics: Acyltransferases; Alanine Transaminase; Antineoplastic Agents; Child; Electrophoresis; Glutamates; H | 1975 |
Combination chemotherapy.
Topics: Adult; Antineoplastic Agents; Child; Cyclophosphamide; Doxorubicin; Drug Therapy, Combination; Fluor | 1975 |
Increased risk of malignant tumors in renal transplant recipients receiving cyclosporine.
Topics: Adult; Azathioprine; Cyclosporine; Female; Humans; Immunosuppression Therapy; Kidney Transplantation | 1992 |
Pneumonia and pneumonitis in childhood malignancy.
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Bacterial Infections; C | 1992 |
Cancer after transplantation in Catalonia.
Topics: Adult; Azathioprine; Cadaver; Cyclosporine; Female; Humans; Immunosuppression Therapy; Kidney Transp | 1992 |
Recent contributions to transplantation at the University of Cincinnati.
Topics: Actuarial Analysis; Adult; Cadaver; Cause of Death; Cyclosporine; Female; Follow-Up Studies; Graft S | 1991 |
Cardiac transplantation in patients with preexisting malignancies.
Topics: Adult; Azathioprine; Cyclosporins; Female; Follow-Up Studies; Graft Rejection; Heart Transplantation | 1991 |
Renal transplantation with cyclosporine in the elderly population.
Topics: Adult; Age Factors; Aged; Antibodies, Monoclonal; Antilymphocyte Serum; Communicable Diseases; Cyclo | 1991 |
Comparative study on lymphocyte subpopulations in cancer patients after immunostimulation with propionibacteria and in renal transplant patients after combined immunosuppression.
Topics: Azathioprine; Globulins; Humans; Immunization; Immunosuppressive Agents; In Vitro Techniques; Kidney | 1990 |
Increased serum selenium levels in patients under corticosteroid treatment.
Topics: Adult; Aged; Dexamethasone; Dose-Response Relationship, Drug; Female; Humans; Lupus Erythematosus, S | 1990 |
Role of mathematical modeling in protocol formulation in cancer chemotherapy.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Dacarbazi | 1985 |
Infusions, age, and drug doses: redux.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Cyclophosphamide; Doxorubici | 1988 |
Pediatric Hodgkin's disease. Later results and toxicity--the Toronto experience.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Combined Modality Therapy; Follow | 1989 |
Extrahepatic malignancy following long-term immunosuppressive therapy of severe hepatitis B surface antigen-negative chronic active hepatitis.
Topics: Azathioprine; Chronic Disease; Female; Hepatitis; Hepatitis B Surface Antigens; Humans; Immunosuppre | 1989 |
[Feasibility of CHOP chemotherapy--with special reference to age, diabetes mellitus, liver cirrhosis and obesity].
Topics: Aged; Aged, 80 and over; Aging; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Di | 1989 |
A phase I trial of interferon-alpha-2a plus cyclophosphamide, vincristine, prednisone, and doxorubicin.
Topics: Adult; Aged; Anemia; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Combined Modality | 1989 |
Treatment of malignancy-associated hypercalcemia with norethisterone: a case report.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Female; Humans; Hypercalcemia; Mid | 1989 |
[Remission with antineoplastic agents?].
Topics: Antineoplastic Combined Chemotherapy Protocols; Humans; Mechlorethamine; Neoplasms; Prednisone; Proc | 1989 |
Current therapy of demyelinating neuropathies.
Topics: Adrenocorticotropic Hormone; Adult; Charcot-Marie-Tooth Disease; Child; Chronic Disease; Combined Mo | 1985 |
The clinical spectrum of inflammatory-angiopathic neuropathy.
Topics: Adolescent; Adult; Aged; Blood Vessels; Collagen Diseases; Female; Humans; Immunosuppressive Agents; | 1986 |
Statistical properties and use of sequential methods in randomized clinical trials when the response criterion is censored.
Topics: Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; | 1988 |
Combination of interferon and prednisone in human cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Body Weight; Drug Tolerance; Humans; Interferon Type | 1988 |
Long-term effects of short-term cyclosporine.
Topics: Adult; Azathioprine; Cyclosporins; Drug Therapy, Combination; Female; Follow-Up Studies; Graft Rejec | 1986 |
Activation of haemostasis by combined chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Hemostasis; Humans; Lymphoma, Non- | 1987 |
[Chemotherapy and ovarian function. Retrospective analysis in 17 girls treated for malignant tumor or hematologic disease].
Topics: Adolescent; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Pre | 1986 |
[Results of a pilot study of hyaluronidase as an adjunct to cytostatic therapy in malignant diseases].
Topics: Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Drug Tolerance; Female; Humans; Hyaluro | 1985 |
[Full-dose CHOP chemotherapy--feasibility and influence upon radiotherapy].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; | 1985 |
Adherence to chemotherapy regimens among children with cancer.
Topics: Adolescent; Child; Female; Humans; Male; Neoplasms; Oncology Nursing; Patient Compliance; Prednisone | 1985 |
Current status and new vistas in combination chemotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Child; Combined Modality Therapy; Hodgkin Disease; H | 1985 |
Neoplasia in immunosuppressed renal transplant patients: a 20-year experience.
Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Azathioprine; Cadaver; Child; Child, Preschool; Cyclo | 1985 |
Cancer in rheumatoid arthritis: a prospective long-term study of mortality.
Topics: Adolescent; Adult; Age Factors; Aged; Arthritis, Rheumatoid; Female; Follow-Up Studies; Gold; Humans | 1985 |
Danazol therapy for autoimmune hemolytic anemia.
Topics: Adolescent; Adult; Aged; Anemia, Hemolytic, Autoimmune; Coombs Test; Danazol; Drug Therapy, Combinat | 1985 |
Response of therapy-associated acute nonlymphocytic leukemia to intensive induction chemotherapy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daun | 1985 |
Immune thrombocytopenia following alpha-interferon therapy in patients with cancer.
Topics: Adult; Blood Platelets; Female; Humans; Immunoglobulins; Interferon Type I; Middle Aged; Neoplasms; | 1985 |
Correctible complications of neoplastic diseases. IV. Autoimmune hemolytic anemia.
Topics: Anemia, Hemolytic, Autoimmune; Blood Transfusion; Dexamethasone; Dicumarol; Glucocorticoids; Hemodyn | 1971 |
Adrenal corticosteroid therapy in far-advanced cancer.
Topics: Adrenal Gland Diseases; Adrenal Glands; Aged; Atrophy; Autopsy; Diabetes Mellitus; Endocarditis; Eso | 1972 |
Perspectives in organ transplantation.
Topics: Adult; Alpha-Globulins; Antigens; Antilymphocyte Serum; Azathioprine; Beta-Globulins; Cadaver; Elect | 1969 |
Failure of corticosteroid therapy to correct the hypercalcaemia of malignant disease.
Topics: Adrenal Cortex Hormones; Adult; Aged; Calcium; Cortisone; Diet Therapy; Female; Humans; Hydrocortiso | 1970 |
[Studies on the problem of the modification of human isoagglutinins with adrenal cortex steroids, x-rays and anti-inflammatory agents].
Topics: Adrenal Cortex Hormones; Drug Therapy; Hemagglutination Tests; Humans; Isoantibodies; Neoplasms; Oxy | 1967 |
Leukocyte (3H) thymidine uptake in short-term whole-blood cultures of human and canine renal allograft recipients.
Topics: Animals; Azathioprine; Cadaver; Dogs; Graft Rejection; Hodgkin Disease; Humans; Immunity, Cellular; | 1973 |
[Position and significance of public health physicians within the medical society from the private physicians' viewpoint].
Topics: Adrenal Cortex Hormones; Aged; Agglutinins; Animals; Autoantibodies; Blood Transfusion; Cats; Cattle | 1973 |
[Therapy of malignant tumors in childhood].
Topics: Adrenocorticotropic Hormone; Antineoplastic Agents; Child, Preschool; Eosinophilic Granuloma; Histio | 1969 |
Chemotherapeutic agents in childhood malignancies.
Topics: Alkaloids; Alkylating Agents; Anti-Bacterial Agents; Antimetabolites; Asparaginase; Child; Humans; L | 1970 |
L-asparaginase in the treatment of neoplastic diseases in children.
Topics: Adolescent; Antineoplastic Agents; Asparaginase; Bone Marrow Examination; Bone Neoplasms; Burkitt Ly | 1971 |
Pediatric oncology.
Topics: Alkylating Agents; Antibiotics, Antineoplastic; Antimetabolites; Asparaginase; Child; Child, Prescho | 1973 |
[Chemotherapy of malignant neoplasms in Internal Medicine Departments].
Topics: Antineoplastic Agents; Drug Therapy, Combination; Humans; Methods; Neoplasms; Prednisone; Procarbazi | 1974 |
[Clinical trial of chemotherapeutic combinations based on the notion of attempted cellular synchronization. Preliminary administration of an antimitotic followed by the use of cycle-dependent or phase dependent product(s)].
Topics: Amino Sugars; Anthraquinones; Antineoplastic Agents; Asparaginase; Cyclophosphamide; Daunorubicin; D | 1972 |
[Chemotherapy of malignant tumors and acute leukoses. New developments and results].
Topics: Antineoplastic Agents; Cyclophosphamide; Drug Therapy, Combination; Hodgkin Disease; Humans; Leukemi | 1972 |
Polymyositis and dermatomyositis.
Topics: Biopsy; Dermatomyositis; Female; Humans; Male; Methotrexate; Muscles; Muscular Diseases; Neoplasms; | 1973 |
Clinical evaluation of equine antithymocyte globulin in recipients of renal allografts: Analysis of survival, renal function, rejection, histocompatibility, and complications.
Topics: Adolescent; Adult; Animals; Antilymphocyte Serum; Azathioprine; Bone Diseases; Child; Evaluation Stu | 1974 |
[Malignant tumors following transplantation. Case reports and review of the literature].
Topics: Adult; Antilymphocyte Serum; Azathioprine; Brain Neoplasms; Female; Graft Rejection; Humans; Kidney | 1973 |
[Theory and practice of systemic cancer therapy].
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Division; Cyclophosphamide; Family Practice; Female; H | 1972 |
[Medical therapy of neoplastic disease. Polychemotherapy and aspecific, active immunostimulation].
Topics: Adjuvants, Immunologic; Adult; Antibody Formation; Antigens; Antineoplastic Agents; BCG Vaccine; Fem | 1973 |
Intensive chemotherapy for Hodgkin's disease: long-term complications.
Topics: Antineoplastic Agents; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; E | 1973 |
[Chemotherapy of malignant tumors].
Topics: Alkylating Agents; Antibiotics, Antineoplastic; Antimetabolites; Antineoplastic Agents; Asparaginase | 1973 |
[Treatment of neoplasms with partial synchronization of cell proliferation].
Topics: Antineoplastic Agents; Drug Interactions; Hodgkin Disease; Humans; Methods; Mitosis; Neoplasms; Nitr | 1974 |
Immunosurveillance and cancer: epidemiological evidence.
Topics: Adolescent; Adult; Age Factors; Aged; Azathioprine; Chediak-Higashi Syndrome; Child; Child, Preschoo | 1970 |
Carcinoma of the testis in a renal transplant recipient.
Topics: Adult; Azathioprine; Cell Transformation, Neoplastic; Humans; Immunosuppressive Agents; Kidney Trans | 1971 |
Chemotherapy in the management of metastatic cancer of unknown primary site.
Topics: Adenocarcinoma; Adolescent; Adult; Aged; Carcinoma; Carcinoma, Squamous Cell; Chlorambucil; Cyclopho | 1972 |
Nonlymphomatous malignant tumors complicating Hodgkin's disease. Possible association with intensive therapy.
Topics: Adolescent; Adult; Antineoplastic Agents; Carcinoma, Squamous Cell; Cyclophosphamide; Drug-Related S | 1972 |
[Studies on calcium metabolism in humans with the aid of a whole body counter. Whole body retention of Ca47 in the healthy and in patients with tumors and other diseases].
Topics: Adult; Age Factors; Aged; Bone Diseases; Bone Neoplasms; Calcium; Calcium Isotopes; Cortisone; Femal | 1971 |
[Delayed hypersensitivity reaction to 2,4-dinitrochlorobenzol in cancer patients undergoing cytostatic chemotherapy].
Topics: Age Factors; Aged; Bronchial Neoplasms; Carcinoma; Cyclophosphamide; Drug Antagonism; Fractures, Bon | 1971 |
[Chimiotherapy of cancers (operational research of its efficiency and its place in therapeutic strategy of neoplasic diseases)].
Topics: Agranulocytosis; Antineoplastic Agents; Bone Marrow; Bone Marrow Cells; Cyclophosphamide; Daunorubic | 1969 |
[Guidelines in the therapy of various neoplastic diseases with cytostatic drugs].
Topics: Alkylating Agents; Antineoplastic Agents; Breast Neoplasms; Bronchial Neoplasms; Gastrointestinal Ne | 1969 |
Dermatomyositis. Importance of early diagnosis.
Topics: Adult; Dermatomyositis; Diagnosis, Differential; Female; Humans; Neoplasms; Prednisone; Trichinellos | 1971 |
Bar-shaped nuclear bodies in oral epithelial cells of children receiving chemotherapy for cancer.
Topics: Adolescent; Adult; Antineoplastic Agents; Child; Child, Preschool; Chromatin; Cyclophosphamide; Daun | 1971 |
Thrombocytosis following thrombocytopenia in man.
Topics: Anemia, Pernicious; Humans; Methotrexate; Neoplasms; Prednisone; Purpura, Thrombocytopenic; Thromboc | 1969 |
Platelet antigens and chemotherapy.
Topics: Agglutination; Antigens; Antimetabolites; Blood Platelets; Female; Humans; Immunosuppressive Agents; | 1970 |
Combined chemotherapy of epithelial tumours.
Topics: Breast Neoplasms; Cobalt Isotopes; Cyclophosphamide; Dactinomycin; DNA, Neoplasm; Female; Humans; Ma | 1970 |
Hypercalcemia associated with neoplastic disease.
Topics: Breast Neoplasms; Bronchial Neoplasms; Carcinoma; Carcinoma, Squamous Cell; Dactinomycin; Electrocar | 1970 |
Malignancy during methotrexate and steroid therapy for psoriasis.
Topics: Adult; Carcinoma, Squamous Cell; Humans; Immunosuppression Therapy; Lung Neoplasms; Male; Methotrexa | 1971 |
Effect of artificially induced abacterial erysipelas and of chronic aseptic abscess on human and experimental neoplasms.
Topics: Abscess; Adult; Aged; Amylases; Anemia; Animals; Breast Neoplasms; Child; Erysipelas; Eye Neoplasms; | 1968 |
Posterior subcapsular cataract (P.S.C.) and systemic steroid therapy.
Topics: Adolescent; Adult; Aged; Cataract; Child; Child, Preschool; Collagen Diseases; Female; Glucocorticoi | 1968 |
[Associated chemotherapeutic treatment of epithelial tumors. Clinical results and doctrinal considerations].
Topics: Adolescent; Adult; Cyclophosphamide; Female; Fluorouracil; Humans; Male; Middle Aged; Neoplasms; Pre | 1969 |
Inhibition of the primary immune response in man by anti-metabolites.
Topics: Antibodies; Antigens; Antimetabolites; Antineoplastic Agents; Humans; Immunosuppressive Agents; Leuk | 1965 |
[Hair melanogenesis in endoxan alopecia and its modification by corticosteroids].
Topics: Alopecia; Breast Neoplasms; Cyclophosphamide; Female; Hair; Humans; Male; Melanins; Neoplasms; Predn | 1966 |